

US010463719B1

(12) **United States Patent**  
**Van Pijkeren et al.**

(10) **Patent No.:** **US 10,463,719 B1**  
(45) **Date of Patent:** **Nov. 5, 2019**

- (54) **MICROORGANISMS AND METHODS FOR PRODUCING BIOLOGICS AND INTRODUCING BIOLOGICS TO SITES**
- (71) Applicant: **WISCONSIN ALUMNI RESEARCH FOUNDATION**, Madison, WI (US)
- (72) Inventors: **Jan Peter Van Pijkeren**, Madison, WI (US); **Jee-Hwan Oh**, Madison, WI (US)
- (73) Assignee: **WISCONSIN ALUMNI RESEARCH FOUNDATION**, Madison, WI (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: **15/819,936**
- (22) Filed: **Nov. 21, 2017**

#### Related U.S. Application Data

- (60) Provisional application No. 62/424,905, filed on Nov. 21, 2016.
- (51) **Int. Cl.**  
**A61K 35/747** (2015.01)  
**A61K 38/47** (2006.01)  
**A61K 38/16** (2006.01)  
**C07K 14/005** (2006.01)  
**C12N 15/74** (2006.01)  
**C12N 7/00** (2006.01)  
**C12N 9/36** (2006.01)
- (52) **U.S. Cl.**  
 CPC ..... **A61K 38/47** (2013.01); **A61K 35/747** (2013.01); **A61K 38/162** (2013.01); **C07K 14/005** (2013.01); **C12N 7/00** (2013.01); **C12N 9/2462** (2013.01); **C12N 15/746** (2013.01); **C12N 2795/10033** (2013.01); **C12N 2830/002** (2013.01)
- (58) **Field of Classification Search**  
 None  
 See application file for complete search history.

#### (56) References Cited

##### U.S. PATENT DOCUMENTS

2010/0124558 A1\* 5/2010 Curtiss, III ..... A61K 35/74  
424/200.1

##### OTHER PUBLICATIONS

Yang Ming-Ming 2006 (Construction and characterization of a novel maltose inducible expression vector in *Bacillus subtilis*; *Biotechnology Letters* 28:1713-1718). (Year: 2006).\*

Alvarez-Sieiro P, Montalbán-López M, Mu D, Kuipers OP. Bacteriocins of lactic acid bacteria: extending the family. *Appl Microbiol Biotechnol.* 2016. 100(7):2939-51.

Bahey-El-Din M, Gahan CGM, Griffin BT. 2010. *Lactococcus lactis* as a cell factory for delivery of therapeutic proteins. *Curr Gene Ther* 10:34-45.

Barrangou R, van Pijkeren JP. Exploiting CRISPR-Cas immune systems for genome editing in bacteria. *Curr Opin Biotechnol.* Feb. 2016;37:61-8.

Becker SC, Dong S, Baker JR, Foster-Frey J, Pritchard DG, Donovan DM. 2009. LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. *FEMS Microbiol Lett* 294:52-60.

Beisel CL, Gomaa AA, Barrangou R. 2014. A CRISPR design for next-generation antimicrobials. *Genome Biol* 15:516.

Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, Fischetti VA, Marraffini LA. 2014.; Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. *Nat Biotech* 32:1146-1150.

Borysowski J, Weber-Dabrowska B, Górski A.; Bacteriophage endolysins as a novel class of antibacterial agents. *Exp Biol Med* (Maywood). Apr. 2006; 231(4):366-77.

Britton, R. A.; Irwin, R.; Quach, D.; Schaefer, L.; Zhang, J.; Lee, T.; Parameswaran, N.; McCabe, L. R.; Probiotic *L. reuteri* Treatment Prevents Bone Loss in a Menopausal Ovariectomized Mouse Model. *J Cell Physiol* 2014, 229 (11), n/a-n/a DOI: 10.1002/jcp.24636.

Chatel J-M, Pothelune L, Ah-Leung S, Corthier G, Wal J-M, Langella P. 2008; In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. *Gene Ther* 15:1184-1190.

Cheng X, Zhang X, Pflugrath JW, Studier FW. 1994. The structure of bacteriophage T7 lysozyme, a zinc amidase and an inhibitor of T7 RNA polymerase. *Proc Natl Acad Sci USA* 91:4034-4038.

Citorik RJ, Mimee M, Lu TK. 2014. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. *Nat Biotech* 32:1141-1145.

Cotter PD, Ross RP, Hill C. 2013. Bacteriocins—a viable alternative to antibiotics? *Nat Rev Microbiol* 11:95-105.

Cronin, M.; Akin, A. R.; Collins, S. A.; Meganck, J.; Kim, J.-B.; Baban, C. K.; Joyce, S. A.; van Dam, G. M.; Zhang, N.; van Sinderen, D.; et al.; High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. *PLoS ONE* 2012, 7 (1), e30940 DOI:1371/journal.pone.0030940.

de Azevedo M, Karczewski J, Lefèvre F, Azevedo V, Miyoshi A, Wells JM, Langella P, Chatel J-M. 2012.; In vitro and in vivo characterization of DNA delivery using recombinant *Lactococcus lactis* expressing a mutated form of *L. monocytogenes* Internalin A. *BMC Microbiol* 12:299.

de Ruyter, P. G.; Kuipers, O. P.; Meijer, W. C.; de Vos, W. M. Food-grade controlled lysis of *Lactococcus lactis* for accelerated cheese ripening. *Nat Biotech* 1997, 15 (10), 976-979 DOI: 10.1038/nbt1097-976.

De Weirtdt R, Crabbé A, Roos S, Vollenweider S, Lacroix C, van Pijkeren J-P, Britton RA, Sarker S, Van de Wiele T, Nickerson CA. 2012.; Glycerol Supplementation Enhances *L. reuteri*'s Protective Effect against *S. Typhimurium* Colonization in a 3-D Model of Colonic Epithelium. *PLoS ONE* 7:e37116.

(Continued)

Primary Examiner — Mary Maille Lyons

(74) Attorney, Agent, or Firm — Daniel A. Blasiolo;  
DeWitt LLP

#### (57) ABSTRACT

Microorganisms comprising a maltose-inducible promoter and methods of use in producing biologics and introducing biologics to sites in a maltose-dependent manner. The microorganisms include a maltose-inducible promoter operably connected to a coding sequence of a biologic. The biologic may be a polypeptide or a nucleic acid. Polypeptide biologics may include lytic proteins and/or secreted proteins. Nucleic acid biologics may include antisense RNA, other types of RNA, or other types of nucleic acids. The microorganisms can be used to produce the biologics and/or introduce the biologics to in vitro or in vivo sites in a maltose-dependent manner. The microorganisms can also be used in maltose-dependent gene silencing.

**19 Claims, 7 Drawing Sheets**

**Specification includes a Sequence Listing.**

(56)

## References Cited

## OTHER PUBLICATIONS

- Dishisha T, Pereyra LP, Pyo S-H, Britton RA, Hatti-Kaul R. 2014. Flux analysis of the *Lactobacillus reuteri* propanediol-utilization pathway for production of 3-hydroxypropionaldehyde, 3-hydroxypropionic acid and 1,3-propanediol from glycerol. *Microb Cell Fact* 13:76.
- Doleyres Y, Beck P, Vollenweider S, Lacroix C. 2005.; Production of 3-hydroxypropionaldehyde using a two-step process with *Lactobacillus reuteri*. *Appl Microbiol Biotechnol* 68:467-474.
- Eaton, K. A.; Honkala, A.; Auchtung, T. A.; Britton, R. A.; Probiotic *Lactobacillus reuteri* Ameliorates Disease Due to Enterohemorrhagic *Escherichia coli* in Germfree Mice. *Infect Immun* 2011, 79 (1), 185-191 DOI: 10.1128/IAI.00880-10.
- Elzagheid, A.; Algars, A.; Bendardaf, R.; Lamlum, H.; Ristamaki, R.; Collan, Y.; Syrjanen, K.; Pyrhonen, S.; E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. *World J Gastroenterol* 2006, 12 (27), 4304-4309.
- Feliza A. Bourguet, Brian E. Souza, Angela K. Hinz, Matthew A. Coleman, and Paul J. Jackson. Characterization of a Novel Lytic Protein Encoded by the *Bacillus cereus* E33L Gene ampD as a *Bacillus anthracis* Antimicrobial Protein. *Appl Environ Microbiol*. Apr. 2012; 78(8): 3025-3027.
- Field D, Begley M, O'Connor PM, Daly KM, Hugenholtz F, Cotter PD, Hill C, Ross RP. 2012. Bioengineered Nisin A Derivatives with Enhanced Activity against Both Gram Positive and Gram Negative Pathogens. *PLoS ONE* 7:e46884.
- Field D, Connor PMO, Cotter PD, Hill C, Ross RP. 2008. The generation of nisin variants with enhanced activity against specific gram-positive pathogens.—PubMed—NCBI. *Mol Microbiol* 69:218-230.
- Fischetti VA. 2004. The use of phage lytic enzymes to control bacterial infections, p. 321-334 in Kutter E, Sulakvelidze A, editors. (ed), *Bacteriophages: biology and applications*. CRC Press, Boca Raton, FL.
- Fischetti VA. 2010. *Bacteriophage Lysins: the Ultimate Enzybiotic; Enzybiotics*. John Wiley & Sons, Inc., Hoboken, NJ, USA.
- Fogel, M. R.; Gray, G. M. Starch hydrolysis in man: an intraluminal process not requiring membrane digestion. *J Appl Physiol* 1973, 35 (2), 263-267.
- Frese, S. A.; Hutkins, R. W.; Walter, J. Comparison of the Colonization Ability of Autochthonous and Allochthonous Strains of *Lactobacilli* in the Human Gastrointestinal Tract. *Advances in Microbiology* 2012, 02 (03), 399-409 DOI: 10.4236/aim.2012.23051.
- Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, Smith HO. 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat Meth* 6:343-345.
- Gomaa AA, Klumpe HE, Luo ML, Selle K, Barrangou R, Beisel CL. 2014. Programmable Removal of Bacterial Strains by Use of Genome-Targeting CRISPR-Cas Systems. *mBio* 5:e00928-13.
- Good L, Stach JE. Synthetic RNA silencing in bacteria—antimicrobial discovery and resistance breaking. *Front Microbiol*. Sep. 12, 2011;2:185.
- Green et al., *Molecular Cloning: A Laboratory Manual*, 4th ed., Cold Spring Harbor Laboratory Press, 2012.
- Guimarães V, Innocentini S, Chatel J-M, Lefèvre F, Langella P, Azevedo V, 582 Miyoshi A. 2009. A new plasmid vector for DNA delivery using lactococci. *Genet Vaccines Ther* 7:4.
- Guimarães, V. D.; Gabriel, J. E.; Lefèvre, F.; Cabanes, D.; Gruss, A.; Cossart, P.; Azevedo, V.; Langella, P. Internalin-expressing *Lactococcus lactis* is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells. *Microbes Infect* 2005, 7 (5-6), 836-844 DOI: 10.1016/j.micinf.2005.02.012.
- Jacobs C, Huang LJ, Bartowsky E, Normark S, Park JT. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta-lactamase induction. *EMBO J*. Oct. 3, 1994; 13(19):4684-94.
- Jacobs C, Joris B, Jamin M, Klarsov K, Van Beeumen J, Mengin-Lecreulx D, van Heijenoort J, Park JT, Normark S, Frère JM.; AmpD, essential for both beta-lactamase regulation and cell wall recycling, is a novel cytosolic N-acetylmuramyl-L-alanine amidase. *Mol Microbiol*. Feb. 1995; 15(3):553-9.
- Kommineni S, Bretl DJ, Lam V, Chakraborty R, Hayward M, Simpson P, Cao Y, Bousounis P, Kristich CJ, Salzman NH. 2015.; Bacteriocin production augments niche competition by enterococci in the mammalian GI tract. *Nature* 526:719-722.
- Lecuit, M.; Ohayon, H.; Braun, L.; Mengaud, J.; Cossart, P. Internalin of *Listeria monocytogenes* with an intact leucine-rich repeat region is sufficient to promote internalization. *Infect Immun* 1997, 65 (12), 5309-5319.
- Liu, Y.; Fatheree, N. Y.; Mangalat, N.; Rhoads, J. M. Human-derived probiotic *Lactobacillus reuteri* strains differentially reduce intestinal inflammation. *Am J Physiol Gastrointest Liver Physiol* 2010, 299 (5), G1087-G1096 DOI: 10.1152/ajpgi.00124.2010.
- Loessner MJ, Kramer K, Ebel F, Scherer S.; C-terminal domains of *Listeria monocytogenes* bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. *Mol Microbiol*. Apr. 2002; 44(2):335-49.
- Loessner MJ.; Bacteriophage endolysins—current state of research and applications. *Curr Opin Microbiol*. Aug. 2005; 8(4):480-7.
- López R, García E, García P, García JL. The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? *Microb Drug Resist*. 1997; 3(2):199-211.
- Navarre WW, Ton-That H, Faull KF, Schneewind O. 1999; Multiple Enzymatic Activities of the Murein Hydrolase from Staphylococcal Phage  $\phi$ 11. *Journal of Biological Chemistry* 274:15847-15856.
- Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA. 2006; PlyC: A multimeric bacteriophage lysin. *Proc Natl Acad Sci USA* 103:10765-10770.
- Nicoletti M, Bertani G. 1983. DNA fusion product of phage P2 with plasmid pBR322: A new phasmid. *Mol Gen Genet* 189:343-347.
- Oh JH, van Pijkeren JP. CRISPR-Cas9-assisted recombineering in *Lactobacillus reuteri*. *Nucleic Acids Res*. 2014;42(17):e131.
- Oh, P. L.; Benson, A. K.; Peterson, D. A.; Patil, P. B.; Moriyama, E. N.; Roos, S.; Walter, J. Diversification of the gut symbiont *Lactobacillus reuteri* as a result of host-driven evolution. *ISME J* 2010, 4 (3), 377-387 DOI: 10.1038/ismej.2009.123.
- Paez-Espino D, Morovic W, Sun CL, Thomas BC, Ueda K-I, Stahl B, Barrangou R, Banfield JF. 2013; Strong bias in the bacterial CRISPR elements that confer immunity to phage. *Nat Comms* 4:1430-1430.
- Pálffy, R.; Gardlík, R.; Hodosy, J.; Behuliak, M.; Resko, P.; Radvánsky, J.; Celec, P.; Bacteria in gene therapy: bactofection versus alternative gene therapy. *Gene Ther* 2006, 13 (2), 101-105 DOI:10.1038/sj.gt.3302635.
- Riboulet-Bisson E, Sturme MHJ, Jeffery IB, O'Donnell MM, Neville BA, Forde BM, Claesson MJ, Harris H, Gardiner GE, Casey PG, Lawlor PG, O'Toole PW, Ross RP. 2012; Effect of *Lactobacillus salivarius* Bacteriocin Abp118 on the Mouse and Pig Intestinal Microbiota. *PLoS ONE* 7:e31113.
- Riedel, C. U.; Monk, I. R.; Casey, P. G.; Morrissey, D.; O'Sullivan, G. C.; Tangney, M.; Hill, C.; Gahan, C. G. M. Improved luciferase tagging system for *Listeria monocytogenes* allows real-time monitoring in vivo and in vitro. *Appl Environ Microbiol* 2007, 73 (9), 3091-3094 DOI:10.1128/AEM.02940-06.
- Robert S, Steidler L. 2014. Recombinant *Lactococcus lactis* can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case. *Microb Cell Fact* 13:S11.
- Schaefer L, Auchtung TA, Hermans KE, Whitehead D, Borhan B, Britten RA. 2010. The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups. *Microbiology* 156:1589-1599.
- Sheehan MM, Stanley E, Fitzgerald GF, van Sinderen D. 1999. Identification and characterization of a lysis module present in a large proportion of bacteriophages infecting *Streptococcus thermophilus*. *Appl Environ Microbiol* 65:569-577.
- Shi, Y.; Yan, Y.; Ji, W.; Bin Du; Meng, X.; Wang, H.; Sun, J. Characterization and determination of holin protein of *Streptococcus suis* bacteriophage SMP in heterologous host. *Virology* 2012, 9 (1), 70-70 DOI: 10.1186/1743-422X-9-70.
- Spinler JK, Taweetchotipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J. 2008. Human-derived probiotic *Lactobacillus reuteri*

(56)

## References Cited

## OTHER PUBLICATIONS

demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. *Anaerobe* 14:166-171.

Steidler L, Hans W, Schotte L, Neiryneck S, Obermeier F, Falk W, Fiers W, 574 Remaut E. 2000. Treatment of Murine Colitis by *Lactococcus lactis* Secreting Interleukin-10. *Science* 289:1352-1355.

Sørvig, Elisabeth, et al. "High-level, inducible gene expression in *Lactobacillus sakei* and *Lactobacillus plantarum* using versatile expression vectors." *Microbiology* 151.7 (2005): 2439-2449.

Sulakvelidze, Alexander; Alavidze, Zemphira; and J. Glenn Morris, Jr. Bacteriophage Therapy. *Antimicrob Agents Chemother.* 2001, 45(3): 649-659.

Summers WC. Bacteriophage therapy. *Annu Rev Microbiol.* 2001; 55:437-51.

Sznol, M.; Lin, S. L.; Bermudes, D.; Zheng, L.-M.; King, I. Use of preferentially replicating bacteria for the treatment of cancer. *Journal of Clinical Investigation* 2000, 105 (8), 1027-1030 DOI:10.1172/JCI9818.

Talarico TL, Casas IA, Chung TC, Dobrogosz WJ. 1988. Production and isolation of reuterin, a growth inhibitor produced by *Lactobacillus reuteri*. *Antimicrob Agents Chemother* 32:1854-1858.

Tannock, G. W.; Wilson, C. M.; Loach, D.; Cook, G. M.; Eason, J.; O'Toole, P. W.; Holtrop, G.; Lawley, B. Resource partitioning in relation to cohabitation of *Lactobacillus* species in the mouse forestomach. *ISME J* 2011, 6 (5), 927-938 DOI: 10.1038/ismej.2011.161.

Thomas, C. M.; Hong, T.; van Pijkeren, J.P.; Hemarajata, P.; Trinh, D. V.; Hu, W.; Britten, R. A.; Kalkum, M.; Versalovic, J.; Histamine

Derived from Probiotic *Lactobacillus reuteri* Suppresses TNF via Modulation of PKA and ERK Signaling. *PLoS ONE* 2012, 7 (2), e31951 DOI:10.1371/journal.pone.0037116.g006.

van Pijkeren JP, Britton RA. High efficiency recombineering in lactic acid bacteria. *Nucleic Acids Res.* May 2012;40(10):e76.

van Pijkeren J-P, Neoh KM, Sirias D, Findley AS, Britton RA. 2012. Exploring optimization parameters to increase ssDNA recombineering in *Lactococcus lactis* and *Lactobacillus reuteri*. *Bioengineered* 3:209-217.

van Pijkeren, J.P.; Britton, R. A. Precision genome engineering in lactic acid bacteria. *Microb Cell Fact* 2014, 13 Suppl 1, S10-S10 DOI: 10.1186/1475-2859-13-S1-S10.

van Pijkeren, J.P.; Morrissey, D.; Monk, I. R.; Cronin, M.; Rajendran, S.; O'Sullivan, G. C.; Gahan, C. G. M.; Tangney, M. A novel *Listeria monocytogenes*-based DNA delivery system for cancer gene therapy. *Hum. Gene Ther.* 2010, 21 (4), 405-416 DOI: 10.1089/hum.2009.022.

Wang IN, Smith DL, Young R. 2000. Holins: the protein clocks of bacteriophage infections. *Annual Reviews in Microbiology*.

Wells M. et al. *Lactococcus lactis*: high-level expression of tetanus toxin fragment C and protection against lethal challenge. *Mol. Microbiol.*, 8 (1993), pp. 1155-1162.

Zhang Y, Eigenbrot C, Zhou L, Shia S, Li W, Quan C, Tom J, Moran P, Di Lello P, Skelton NJ, Kong-Beltran M, Peterson A, Kirchhofer D. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. *J Biol Chem.* Jan. 10, 2014;289(2):942-55.

Zhou, Y.; Liang, Y.; Lynch, K. H.; Dennis, J. J.; Wishart, D. S. PHAST: A Fast Phage Search Tool. 2011, 39 (suppl), W347-W352 DOI: 10.1093/nar/gkr485.

\* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5






FIG. 6




FIG. 7

1

## MICROORGANISMS AND METHODS FOR PRODUCING BIOLOGICS AND INTRODUCING BIOLOGICS TO SITES

### FIELD OF THE INVENTION

The invention is directed to microorganisms and methods for producing biologics and introducing biologics to sites, including in vivo sites such as the gastrointestinal tract or in vitro sites.

### BACKGROUND

The application of microorganisms for in situ delivery of therapeutics was first demonstrated by (Steidler et al. 2000) with lactic acid bacteria. The cheese bacterium *Lactococcus lactis* was engineered to secrete murine interleukin-10 (mIL10). Oral administration of the recombinant lactic acid bacterium significantly reduced intestinal inflammation in two mouse models of disease. The authors demonstrated mIL-10 was detected in the colon of IL10<sup>-/-</sup> mice and that the therapeutic effect was obtained following de novo synthesis of IL-10 by *L. lactis* during gastrointestinal (GI) transit. Since then, the *L. lactis* workhorse has been exploited to deliver a variety of recombinant proteins (Bahay-El-Din et al. 2010, Robert et al., 2014) and DNA (Guimarães et al. 2009, Chatel et al. 2008, de Azevedo et al., 2012), and has paved the way to harness other microbes as delivery vehicles. In particular, engineering food-grade microorganisms that can survive passage through the gastrointestinal tract, and naturally encode health-promoting properties, collectively provides a promising platform to deliver biologics of interest.

There are at least two challenges, however, to using microorganisms as biologic delivery vehicles. A first challenge is obtaining specificity in the delivery of biologics at therapeutic amounts, either with respect to particular sites in the body or within particular timeframes after administration. A second challenge is biologically containing the microorganisms. Biologic delivery vehicles that address these challenges are needed.

### SUMMARY OF THE INVENTION

The present invention addresses the aforementioned challenges. The present invention provides microorganisms and methods for introducing biologics to a site upon stimulation with an environmental cue. The microorganisms of the invention employ a maltose-inducible promoter to stimulate production and/or release of biologics at the site upon exposure to maltose. Accordingly, the microorganisms can be used as a delivery platform to introduce biologics to sites that have a sufficient amount of maltose present to stimulate production and/or release of the biologics. The microorganisms can also be used as a delivery platform to deliver biologics to sites that do not have a sufficient amount of maltose present to stimulate production and/or release of the biologics. This can be done by “priming” the microorganisms with maltose prior to introducing the microorganisms to the site. The priming induces transcription and thereby permits production and/or release of biologics at later points in time to sites having no or low concentrations of maltose.

In some versions of the invention, the microorganisms are used as delivery vehicles to introduce biologics to in vivo sites, such as the gastrointestinal tract. The microorganism can be administered to the gastrointestinal tract orally or by other routes. Maltose present in the gastrointestinal tract

2

simulates production and/or release of the biologics therein. To help induce production and/or release of the biologics, maltose levels in the gastrointestinal tract can be increased by administering maltose or a maltose precursor, such as starch, to the gastrointestinal tract. Alternatively or additionally, the microorganisms can be exposed to a maltose-rich medium to induce transcription prior to being administered to the gastrointestinal tract.

In other versions of the invention, the microorganisms are used to produce biologics in vitro. The microorganisms can be cultured in the presence of a sufficient amount of maltose present to stimulate product and/or release of the biologics.

The microorganisms of the invention can be configured to introduce biologics to a site in any of a number of formats. In some versions, the microorganisms are configured to secrete a secretable biologic in a maltose-dependent manner. In these versions, production of the secretable biologic is dependent on expression of one or more genes controlled by the maltose-inducible promoter such that the secretable biologic is produced and secreted upon exposure to maltose.

In other versions, the microorganisms are configured to constitutively produce a therapeutic biologic intracellularly but release the therapeutic biologic primarily in a maltose-dependent manner. In these versions, the microorganisms may comprise a maltose-dependent promoter operably connected to a nucleic acid sequence encoding a lytic protein that promotes lysis of the microorganism upon exposure to maltose. Exposure to maltose drives expression of the lytic protein, induces lysis of the microorganism, and facilitates release of the biologic.

In yet other versions, the microorganisms are configured both to produce a therapeutic biologic and to induce lysis in a maltose-dependent manner. In these versions, production of the biologic is dependent on expression of one or more genes controlled by the maltose-inducible promoter such that the biologic is produced upon exposure to maltose. The microorganisms also comprise a maltose-dependent promoter operably connected to a nucleic acid sequence encoding a lytic protein that promotes lysis of the microorganism upon exposure to maltose. Exposure to maltose drives expression of the lytic protein, induces lysis of the microorganism, and facilitates release of the biologic. There is typically a lag between induction of the lytic protein and cell lysis, which leaves time for intracellular production of the biologic before lysis.

In some versions of the invention, the microorganisms are configured to produce a biologic in a maltose-dependent manner regardless of whether or not the microorganism is configured for lysis.

The objects and advantages of the invention will appear more fully from the following detailed description of the preferred embodiment of the invention made in conjunction with the accompanying drawings.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schema outlining an exemplary version of the invention, wherein a microorganism is modified for use as a biologic delivery vehicle. The microorganism is a *Lactobacillus reuteri* that produces a pathogen-specific bacteriophage as an exemplary biologic and harbors a maltose (mal)-sensitive lytic protein gene (e.g., holin and/or lysin). Maltose exposure leads to expression of the lytic protein gene, which, in turn, causes lysis of the microorganism and release of the biologic into the surroundings.

FIG. 2 shows lysis of *L. reuteri* mediated by holin expressed from an inducible promoter as an exemplary lytic



## 5

DNA vaccines, RNA-based therapeutics, RNA aptamers, RNA Decoys, antisense RNA, ribozymes, small interfering RNAs, and microRNAs, among others.

Exemplary viruses include bacteriophages, including antimicrobial bacteriophages. See, for example, (Sulakvelidze et al. 2001, Summers 2001, Borysowski et al. 2006, and Fischetti 2004). Since their discovery nearly a century ago, bacteriophages have been exploited to kill select microbes, which can be attributed to production of holins and/or endolysins. Historically, bacteriophage therapy was mainly focused in Eastern Europe whereas in the US the wide application of antibiotics was preferred (Sulakvelidze et al. 2001). However, the emerging and rapidly expanding threat of antibiotic-resistance has led to a revival of the use of bacteriophages in therapy.

Exemplary antimicrobial bacteriophages include those employing the CRISPR-Cas system to specifically target certain bacteria. CRISPR-Cas can be repurposed for applications such as programmable antimicrobials (Gomaa et al. 2014). What renders CRISPR machines desirable for genome editing in eukaryotes, makes them lethal antimicrobials in prokaryotes (Beisel et al. 2014). The paucity of DNA repair mechanisms in bacteria compared to eukaryotes renders bacteria highly susceptible to DNA damage, including CRISPR-induced DNA breaks and nicks. Therefore, self-targeting CRISPR spacers are highly lethal, and selected against during accidental acquisition of spacers from the host chromosome (Paez-Espino et al. 2013). This provides the opportunity for repurposing endogenous or exogenous CRISPR-Cas systems for self-targeting in bacteria, as programmable and specific antimicrobials (Gomaa et al. 2014).

Type I and Type II CRISPR-Cas systems harnessing both native and heterologous Cas nucleases have been generated in vivo and in vitro (Gomaa et al. 2014, Bikard et al. 2014, Citorik et al. 2014). However, a primary challenge in employing this technology is in-situ delivery of the bacteriophages to sites in the body—especially in the gastrointestinal tract. The microorganisms provided herein provide a solution to this challenge. The microorganisms described herein can be engineered as Trojan horses for the local delivery of engineered bacteriophages that carry CRISPR-cassette for self-targeting in pathogenic bacteria. A hybrid between a plasmid and a bacteriophage can be engineered to yield a phasmid for heterogenic bacteriophage production in the microorganism. The generation of a phasmid was already demonstrated 3 decades ago by fusion of the *E. coli* bacteriophage P2 with plasmid pBR322 (Nicoletti et al. 1983). Replication of the phasmid can be established from either the plasmid replication proteins, or from the bacteriophage replication proteins. Regardless of the modus of replication, functional virions can be produced. With the development of high-throughput assembling technologies, such as Gibson assembly (Gibson et al. 2009), building synthetic DNA fragments such as phasmids containing double-stranded bacteriophage DNA are a suitable approach. A CRISPR-array specific for a pathogen to be targeted can be embedded in the bacteriophage genome for packaging (Bikard et al. 2014, Citorik et al. 2014). Once the phasmid is established in the probiotic, virions are produced in the cytosol. Release of the virions in situ can occur using the modules and mechanisms described herein (e.g., a maltose-inducible promoter fused to a lytic protein gene to lyse the microorganism and release the engineered virions). The released virions will inject the DNA in the target pathogen to deliver the CRISPR-array, which, when combined with the native Cas proteins, will yield strain-specific killing.

## 6

Suitable polypeptide biologics may include any polypeptide of interest. The polypeptide may have any of a number of amino acid chain lengths. In some versions, the polypeptide may have an amino acid chain length of from about 2 to about 2,000 amino acids, from about 2 to about 1,000 amino acids, from about 2 to about 500 amino acids, from about 3 to about 250 amino acids, or from about 3 to about 225 amino acids. The polypeptide may have a net positive charge at neutral pH, a net negative charge at neutral pH, or a net neutral charge at neutral pH. The polypeptide is preferably soluble in water. The polypeptide may form a globular or fibrous structure or may have an intrinsically disordered structure.

The polypeptide may have any of a number of functionalities. The polypeptide, for example, may be enzymatic or non-enzymatic. The polypeptide may be fluorescent or non-fluorescent. The polypeptide may be a cytokine, a hormone, an antibody, an antimicrobial peptide, and an antigenic peptide, among others.

Exemplary classes of cytokines include interleukins, lymphokines, monokines, interferons (IFNs), colony stimulating factors (CSFs), among others. Specific exemplary cytokines include IL-1 alpha (IL1a), IL-1 beta (IL1b), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-35, IL-36, IFN-alpha, IFN-beta, IFN-gamma, TNF-alpha, TNF-beta, CNTF (C-NTF), LIF, OSM (oncostatin-M), EPO (erythropoietin), G-CSF (GCSF), GM-CSF (GMCSF), M-CSF (MCSF), SCF, GH (growth hormone), PRL (prolactin), aFGF (FGF-acidic), bFGF (FGF-basic), INT-2, KGF (FGF7), EGF, TGF-alpha, TGF-beta, PDGF, betacellulin (BTC), SCDGF, amphiregulin, and HB-EG, among others.

Exemplary hormones include epinephrine, melatonin, triiodothyronine, thyroxine, amylin (or islet amyloid polypeptide), adiponectin, adrenocorticotrophic hormone (or corticotropin), angiotensinogen, angiotensin, antidiuretic hormone (or vasopressin, arginine vasopressin), atrial natriuretic peptide (or atriopeptin), brain natriuretic peptide, calcitonin, cholecystokinin, corticotropin-releasing hormone, cortistatin, enkephalin, endothelin, erythropoietin, follicle-stimulating hormone, galanin, gastric inhibitory polypeptide, gastrin, ghrelin, glucagon, glucagon-like peptide-1, gonadotropin-releasing hormone, growth hormone-releasing hormone, hepcidin, human chorionic gonadotropin, human placental lactogen, growth hormone, inhibin, insulin, insulin-like growth factor (or somatomedin), leptin, lipotropin, luteinizing hormone, melanocyte stimulating hormone, motilin, orexin, oxytocin, pancreatic polypeptide, parathyroid hormone, pituitary adenylate cyclase-activating peptide, prolactin, prolactin releasing hormone, relaxin, renin, secretin, somatostatin, thrombopoietin, thyroid-stimulating hormone (or thyrotropin), thyrotropin-releasing hormone, and vasoactive intestinal peptide, among others.

Other physiologically active peptides include tachykinin peptides, such as substance P, kassinin, neurokinin A, eleoisin, and neurokinin B; peptide PHI 27 (peptide histidine isoleucine 27); pancreatic polypeptide-related peptides, such as NPY (neuropeptide Y), PYY (peptide YY), and APP (avian pancreatic polypeptide); opioid peptides, such as proopiomelanocortin (POMC) peptides and prodynorphin peptides; AGG01; B-type natriuretic peptide (BNP); lactotripeptides; and peptides that inhibit PCSK9 (Zhang et al. 2014).

Exemplary antibodies include single-chain antibodies, single-domain antibodies (sdAbs), and single-chain variable fragments (scFvs).

Exemplary antimicrobial peptides include cathelicidins, defensins, protegrins, mastoparan, poneratoxin, cecropin, moricin, melittin, magainin, dermaseptin, nisin, and others. Other antimicrobial peptides include regIII- $\beta$  and reg-III- $\gamma$ , which are eukaryotic antimicrobial peptides produced in the intestine. Lactic acid bacteria are well known for their extensive heterogenic repertoire of antimicrobial compounds, including bacteriocins (Alvarez-Sieiro et al. 2016).

Other exemplary biologics include peptides that play a role in degrading bacterial cell walls, such as holins and lysins.

Other exemplary biologics include any of a number of antimicrobials produced (either naturally or via engineering) by microorganisms. Lactic acid bacteria, for example, are well-known for their extensive heterogenic repertoire of antimicrobial compounds, including bacteriocins (Alvarez-Sieiro et al. 2016). Bacteriocins are small ribosomally-synthesized peptides that can inhibit or kill bacteria. The functional diversity of this family of antimicrobials is large, which is illustrated by the fact that bacteriocins can collectively target a wide-array of Gram-negative and Gram-positive bacteria (Cotter et al. 2013).

Although narrow-spectrum bacteriocins may be preferential, the application of broad-spectrum bacteriocins may be useful to alleviate a bacterial infection of unknown source. Bacteriocin-mediated impact on the gut microbiota composition can be substantial. This was demonstrated for Abp118, a broad-spectrum bacteriocin produced by *L. salivarius* UCC118 (Riboulet-Bisson et al. 2012). By comparing the microbiota in mice and pigs between groups that were administered with *L. salivarius* wild-type or *L. salivarius* $\Delta$ abp118, it was confirmed that the presence of the bacteriocin-producing lactobacilli alters the gut microbiota composition without significance changes in microbial diversity. This study, and that of others (Kommineni et al. 2015), demonstrates that a bacteriocin-producing probiotic can eradicate select members of the gut microbiota, providing a rationale to engineer bacteriocins for enhanced efficacy.

One example of a useful bacteriocin is nisin, which is produced by select *Lactococcus lactis* strains and streptococci. The 372 basepair gene encoding nisin (nisA), one of the six natural nisin variants, was subjected to site-directed and saturation mutagenesis, and mutants were recovered that displayed enhanced activity against Gram-positive and Gram-negative pathogens (Field et al. 2008, Field et al. 2012). The above-described methodology was based on modification of a plasmid-encoded nisin by PCR. Recent developments now enable codon saturation mutagenesis in the chromosome. In *L. reuteri*, single-stranded DNA recombineering can be combined with CRISPR-Cas selection, which allows one-step codon saturation mutagenesis (Oh et al. 2014). A single transformation of an oligonucleotide containing the NNK motif (N=A/T/G/C and K=G/T) yielded a pool of recombinants in which a single codon was modified to encode for all 20 amino acids. These approaches can be multiplexed to accelerate the discovery of probiotics with enhanced anti-microbial activity.

Rather than using codon mutagenesis to identify novel anti-microbial variants, genetic engineering approaches can also be applied to enhance the production of the antimicrobial. This was previously demonstrated for reuterin, also known as 3-hydroxypropionaldehyde (3-HPA) (van Pijkeren and Neoh et al. 2012). Select *L. reuteri* strains produce

reuterin as an intermediate during glycerol fermentation to produce 1,3-propanediol (Doleyres et al. 2005). Reuterin has a broad-spectrum activity (Spinler et al. 2008, De Weirdt et al. 2012, Talarico et al. 1988). The gene cluster responsible for 1,3-propanediol production (and thus reuterin) is the propanediol utilization (pdu) operon. By single-stranded DNA recombineering six bases were modified in the promoter region driving expression of the pdu operon. The recombinant strain produced more reuterin (Dishisha et al. 2014, van Pijkeren and Britton et al. 2012, van Pijkeren and Neoh et al. 2012), resulting in 3-fold increased killing efficacy of *E. coli* compared to the wild-type strain (van Pijkeren and Neoh et al. 2012). Also, deletion of the gene encoding 1,3-propanediol reductase, which is responsible for the conversion of reuterin to 1,3-propanediol, yielded approximately 4-fold more reuterin compared to the wild-type (Schaefer et al. 2010). A double mutant derivative in which increased expression of the pdu operon is combined with deletion of the 1,3-propanediol reductase gene can yield a tailored probiotic with superior in-vivo killing activity.

Preferred versions of the invention make use of a maltose-inducible promoter for introducing a biologic to a particular site. As used herein, “introduce” and its grammatical equivalents, when used in reference to an element such as a microorganism or a biologic, refers to any activity that results in the initial appearance or increased appearance of the element at the site. Introducing microorganisms to a site may comprise, for example, inoculating, administering, culturing, and growing the microorganism at that site. Introducing biologics to a site may comprise, for example, stimulating production of the biologics and/or release of the biologics at the site.

An exemplary maltose-inducible promoter is represented by SEQ ID NO:1, which is a maltose-inducible promoter found in *L. reuteri*:

(SEQ ID NO: 1)

```
TACCAAGAATAACTTTTCATCGTAAAAGGCAAGTAATTGAGGAACTTGAA
GTTTTTCTCTATTACTTGCCTTCTTTATTTTATTAAGCTAAATATGTTTT
AAATAATTAACATAACGGACCTGCTTGGCGGAACTAAACAGTAAGAAC
TTTAAATTATAAAAATCTGCAACCGTTTTCTAAAATTTGCGCAAGCGGT
TGCGCAAAAATTTTAAATTTGATATTATTAATATTGCAATAATTCATGAA
GCGCTTACAATAATCACAAGTGTCTTTTAGAACTATTTTATAAGTTAAGG
AGTTGTTAGCA
```

The maltose-inducible promoter represented by SEQ ID NO:1 or variants thereof are suitable for use in the present invention. Variants of SEQ ID NO:1 include sequences at least about 80% identical, at least about 83% identical, at least about 85% identical, at least about 87% identical, at least about 90% identical, at least about 83% identical, at least about 95% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to SEQ ID NO:1

In some versions of the invention, the maltose-inducible promoter is operably connected to a coding sequence of a gene product. The maltose-inducible promoter can be operably connected to the coding sequence of any biologic described herein. As used herein, “gene product” refers to any product resulting from expression (e.g., transcription or transcription and translation) of a gene. The term “gene product” explicitly encompasses polypeptides as well as

nucleic acids such as RNA (e.g., mRNA, pri-microRNA, pre-microRNA, microRNA, antisense RNA (asRNA) etc.) and DNA (cDNA). “Coding sequence” refers to a nucleic acid in the gene that encodes the gene product. The term “coding sequence” encompasses sequences that include codons that are ultimately transcribed and translated into polypeptides as well as sequences that do not include codons and/or are merely transcribed (e.g., antisense RNA, etc.). “Gene” refers to any collection of genetic elements involved in expressing a coding sequence and may include, in addition to the coding sequence, a promoter, a ribosomal binding site, an enhancer, etc. The term “gene” encompasses genetic elements that are transcribed into mRNA and translated into polypeptides as well as genetic elements that are merely transcribed into various types of RNA (e.g., microRNA, antisense RNA, etc.). “Promoter” refers to any nucleic acid that confers, activates, or enhances expression of an operably connected coding sequence. “Operably connected” generally refers to a connection of two genetic elements in a manner wherein one can operate on or have effects on the other. “Operably connected” used in reference to a promoter and a coding sequence refers to a connection between the promoter and the coding sequence such that the coding sequence is under transcriptional control of the promoter. For example, promoters are generally positioned 5' (upstream) of a coding sequence to be operably connected to the promoter. In the construction of heterologous promoter/coding sequence combinations, it is generally preferred to position the promoter at a distance from the transcription start site that is approximately the same as the distance between that promoter and the coding sequence it controls in its natural setting, i.e., in the gene from which the promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of promoter function.

In some versions of the invention, the maltose-inducible promoter is operably connected to the coding sequence of a lytic protein as a biologic. As used herein, “lytic protein” refers to any protein that causes or aids, either directly or indirectly, in the lysis of a microorganism. Operably connecting the maltose-inducible promoter to the coding sequence of a lytic protein induces lysis of the microorganism, release of the lytic protein, and release of any other biologics made by the microorganism in a maltose-dependent manner. Such release can occur, for example, in the gastrointestinal tract due to natural levels of maltose therein, or in other sites of the body with low levels of maltose due to maltose priming, as discussed in further detail below. Such release can also occur *in vitro*, whether in the presence of high levels of maltose or in the presence of low or no levels of maltose due to maltose priming.

Lytic proteins are well known in the art. A number of lytic proteins, for example, are found in bacteriophages and serve to lyse microorganisms during the lytic stages of the bacteriophage’s life cycle. These include holins and lysins (Sheehan et al. 1999). During bacteriophage replication, biologically active lysins are present in the cytosol but require expression of a membrane protein, holin, to release the virions from the cell. When holin levels are optimal, the lysin can access the peptidoglycan layer for cleavage which leads to bacterial cell lysis (Wang et al. 2000). So far, five main groups of lysins have been identified that can be distinguished from one and another based on the cleavage specificity of the different bonds within the peptidoglycan (Fischetti 2009). Structurally, lysins can comprise a single catalytic domain, which generally is typical for lysins derived from bacteriophages targeting Gram-negative bac-

teria (Cheng et al. 1994). Bacteriophages targeting Gram-positive bacteria typically encode lysins that contain multiple domains: a N-terminal catalytic domain and a C-terminal cell-wall binding domain (Nelson et al. 2006, Navarre et al. 1999). A few lysins have been identified that have three domains (Becker et al. 2009).

A number of other lytic proteins are native to the microorganisms themselves (Feliza et al. 2012, Jacobs et al. 1994, Jacobs et al. 1995, López et al. 1997). These lytic proteins may affect cell wall metabolism or introduce nicks in the cell wall. Five protein classes are differentiated by the wall component they attack (Loessner et al. 2005, Loessner et al. 2002).

In some versions of the invention, the microorganism is configured to constitutively express a lysin and to express a holin in a maltose-dependent manner. In some versions, the microorganism is configured to express both a lysin and a holin in a maltose-dependent manner.

In certain versions of the invention, maltose-dependent lysis of the microorganism serves to release one or more additional biologics made by the microorganism other than the lysis protein. The microorganism may naturally produce such additional biologics or may be genetically modified to produce or enhance production of the additional biologics. The one or more additional biologics may comprise any one or more of the biologics described herein or otherwise known in the art. The additional biologics may be produced in a maltose-dependent manner or in a maltose-independent manner. For example, a gene responsible for making the biologic, either directly or indirectly, can be controlled by a maltose-inducible promoter or with any other inducible or constitutive promoter. The maltose-inducible promoter may be operably connected to a coding sequence of an additional biologic itself such that production of the biologic is directly controlled by the maltose-inducible promoter. The maltose-inducible promoter may alternatively be operably connected to one or more coding sequences of factors responsible for producing an additional biologic such that production of the biologic is indirectly controlled by the maltose-inducible promoter. The additional biologics may be non-secreted biologics, meaning that the biologics may be substantially inhibited from being released from the microorganism until the microorganism is lysed.

In some versions of the invention, the microorganism is configured to produce a biologic in a maltose-dependent manner regardless of whether or not the biologic is ultimately released from the microorganism through lysis. For example, the maltose-inducible promoter may be operably connected to a gene product that is produced within the microorganism without substantial release therefrom. The gene product may be internally contained within the microorganism for an extended period of time. The gene product may include any gene product described herein, including any polypeptide and any nucleic acid. The produced gene products may have a functional effect on the microorganism.

The maltose-inducible promoter, for example, may be used for maltose-inducible gene silencing with the use of antisense RNA (asRNA). The antisense RNA may include cis-encoded asRNA or trans-encoded asRNA. Cis-encoded asRNA can be obtained by cloning the maltose-inducible promoter on the opposing DNA strand and in the opposite orientation of a gene of interest. Trans-encoded asRNA can be obtained by cloning the maltose-inducible promoter in front of an asRNA-producing coding sequence at a locus (elsewhere in the genome or from a plasmid, etc.) other than where the gene of interest resides.

A schema showing maltose-inducible gene silencing using cis-encoded or trans-encoded asRNA is provided in FIG. 7. In the presence of glucose (top panel of FIG. 7), there is no production of cis-encoded (left side of FIG. 7) or trans-encoded (right side of FIG. 7) antisense RNA (asRNA). Thus, gene-of-interest (*goiA*) mRNA is produced which will lead to production of the protein (*GoiA*). Activation of the promoter by maltose (bottom panel in FIG. 7) leads to production of cis-encoded asRNA (left side of FIG. 7) or trans-encoded asRNA (right side of FIG. 7). In nature, and as depicted in the FIG. 7, trans-encoded asRNA has limited complementarity with the mRNA and requires the RNA chaperon Hfq to facilitate binding. However, the trans-encoded asRNA can be user-defined and is therefore not a limitation for the application of the maltose-inducible trans-encoded asRNA expression. Once the asRNA (cis- or trans-) is bound to the target mRNA, there are different processes that can contribute to reduce translation. This can be achieved through blocking binding to the ribosomal binding site (RBS) (i in FIG. 7), through RNase-mediated degradation of the mRNA:asRNA complex (ii in FIG. 7), or both. For further aspects of employing gene silencing with asRNA, see Good et al. 2011. One of skill in the art is readily capable of identifying antisense sequences for any gene of interest.

Any of the biologics made by the microorganism may be produced from a recombinant gene. "Recombinant" used in reference to a gene refers herein to a sequence of nucleic acids that are not naturally occurring in the genome of the microorganism. The non-naturally occurring sequence may include a recombination, substitution, deletion, or addition of one or more bases with respect to the nucleic acid sequence originally present in the natural genome of the bacterium. The recombinant gene may be incorporated into the chromosome of the microorganism or may be included on an extra-chromosomal plasmid. The extra-chromosomal plasmid may replicate at any copy number in the cell and, accordingly, be a single-copy plasmid, a low-copy plasmid, or a high-copy plasmid. The extra-chromosomal plasmid is preferably substantially stable within the microorganism. The rate of loss of the extra-chromosomal plasmid from the microorganism is preferably less than about 10% per generation, less than about 5% per generation, or less than about 1% per generation, wherein percent per generation refers to the percent of the population per generation in which the plasmid is lost.

In some versions, stability of an extrachromosomal plasmid in a microorganism is established by including an antibiotic marker on the plasmid and selecting for microorganisms harboring the plasmid with the antibiotic. Such selection can occur in vitro and in vivo. As administration of antibiotics can be undesired in some cases, stability of the extrachromosomal plasmid in the microorganism can be established in an antibiotic-independent manner. An exemplary method of establishing stability of the extrachromosomal plasmid in the microorganism in an antibiotic-independent manner is by inducing auxotrophy in the microorganism with respect to a factor limited or absent in its surroundings and including a gene that resolves that auxotrophy on the extrachromosomal plasmid. An example of this method is provided in the examples, in which *thyA* is deleted from *L. reuteri* but is included on an extrachromosomal plasmid harbored by the *L. reuteri*.

An exemplary extrachromosomal plasmid containing a recombinant, maltose-inducible gene for holin as a biologic is provided by SEQ ID NO:2, a schema of which is shown in FIG. 3:

(SEQ ID NO: 2)

TAATCTAGACTCGAGGAATTCGGTACCCCGGGTTCTGAAGGCGCCAAGCTT  
 CAAATTACAGCACGTGTGCTTTGATTGATAGCCAAAAAGCAGCAGTTGA  
 5 TAAAGCAATTACTGATATTGCTGAAAAATTGTAATTTATAAATAAAAAATC  
 ACCTTTTAGAGGTGGTTTTTTTTATTATAAATTTATTCGTTTGATTTCGCT  
 TTCGATAGAACAATCAAAGCGAGAATAAGGAAGATAAATCCCATAGGGC  
 10 GGGAGCAGAATGTCCGAGACTAATTCATGAGATCGATTTTTTTATTAATAAC  
 GTCTCAAATCGTTTCTGAGACGTTTTAGCGTTTATTCGTTTAGTTATC  
 GGCATAATCGTTAAAAACAGGCGTTATCGTAGCGTAAAAGCCCTTGAGCGT  
 15 AGCGTGCTTTGCAGCGAAGATGTTGTCTGTTAGATTATGAAAGCCGATGA  
 CTGAATGAAATAATAAGCGCAGCGTCTTCTATTTTCGGTTGGAGGAGGCT  
 CAAGGGAGTTTGAGGGAATGAAATTCCTCATGGGTTTGATTTTAAAAAT  
 20 TGCTTGCAATTTTGCCGAGCGGTAGCGCTGGAAAAATTTTGAAAAAAT  
 TTGGAATTTGAAAAAATGGGGGAAAGGAAGCGAATTTGCTTCCGTA  
 CTACGACCCCCATTAAGTGCCGAGTGCCAATTTTGTGCCAAAAACGCT  
 25 CTATCCCAACTGGCTCAAGGGTTTGAGGGGTTTTTCAATCGCCAACGAAT  
 CGCCAACGTTTTTCGCCAACGTTTTTTATAAATCTATATTTAAGTAGCTTT  
 ATTGTTGTTTTTATGATTACAAAGTGATACACTAATTTTATAAAATTTATT  
 30 TGATTGAGTTTTTTAAATGGTGATTCAGAATCGAAAAAAGAGTTATG  
 ATTTCTCTGACAAAAGAGCAAGATAAAAAATTAACAGATATGGCGAAACA  
 AAAAGGTTTTTCAAATCTGCGGTTGCGGCTTAGCTATAGAAGAATATG  
 35 CAAGAAAGGAATCAGAATAAAAAAATAAGCGAAAGCTCGCGTTTTTAGA  
 AGGATACGAGTTTTTCGCTACTTGTTTTTGATAAGGTAATATATCATGGCT  
 ATTAATACTAAAGCTAGAAATTTTGGATTTTTATTATATCTGACTCAA  
 40 TTCCTAATGATTGAAAGAAAAATTAGAGAGTTTGGGCGTATCTATGGCT  
 GTCAGTCTTTTACACGATATGGACGAAAAAAGATAAAGATACATGGAA  
 TAGTAGTGATGTTATACGAAATGGAAAGCACTATAAAAAACCACACTATC  
 45 ACGTTATATATATTGCACGAAATCCTGTAACAATAGAAAGCGTTAGGAAC  
 AAGATTAAGCGAAAAATTGGGAATAGTTCAGTTGCTCATGTTGAGATACT  
 TGATTATATCAAAGGTTTATATGAATATTTGACTCATGAATCAAAGGACG  
 CTATTGCTAAGAATAAACATATATACGACAAAAAAGATTTTTGAACATT  
 50 AATGATTTTGATATTGACCGCTATATAACACTTGATGAAAGCCAAAAAAG  
 AGAATTGAAGAATTTACTTTTAGATATAGTGGATGACTATAATTTGGTAA  
 ATACAAAAGATTTAATGGCTTTTTATTGCGCTTAGGGGAGCGGAGTTTGA  
 55 ATTTTAAATACGAATGATGTAAAAGATATTGTTTCAACAACTCTAGCGC  
 CTTTAGATTATGGTTTGAGGGCAATTATCAGTGTGGATATAGAGCAAGTT  
 ATGCAAAGGTTCTTGATGCTGAAACGGGGGAAATAAATGACAAACAAAG  
 60 AAAAAGAGTTATTTGCTGAAAATGAGGAATTAATAAAGAAATTAAGGAC  
 TTAAAAGAGCGTATTGAAAGATACAGAGAAATGGAAGTTGAATTAAGTAC  
 AACAAATAGATTTATTGAGAGGAGGGATTATTGAATAAATAAAGCCCCC  
 65 TGACGAAAGTCGAAGGGGCTTTTATTTGGTTTGATGTTGCGATTAATA



13

-continued

GCAATACGATTGCAATAAAACAAAATGATCCCCTTAGAAGCAAACCTTAAGA  
 GTGTGTTGATAGTGCATTATCTTAAAATTTTGTATAATAGGAATTGAAGT  
 TAAATTAGATGCTAAAAATAGGAATTGAAGTTAAATTAGATGCTAAAAAT  
 5 TTGTAATTAAGAAGGAGGGATTTCGTGATGTTGGTATTCCAAATGCGTAAT  
 GTAGATAAAACATCTACTGTTTGAACAGACTAAAAACAGTGATTACGC  
 AGATAAATAAATACGTTAGATTAATTCCTACCAGTGACTAATCTTATGAC  
 10 TTTTAAACAGATAACTAAAATTACAAACAAATCGTTTAACTTCAGGAGA  
 GATTACATGAACAAAAATATAAATACTCAAACCTTTTAAACGAGTGAAAA  
 AGTACTCAACCAAATAATAAAACAATTGAATTTAAAAGAAAACCGATACCG  
 15 TTTACGAAATTGGAACAGGTAAAGGGCATTAAACGACGAAACTGGCTAAA  
 ATAAGTAAACAGGTAACGTCTATTGAATTAGACAGTCATCTATTCAACTT  
 ATCGTCAGAAAAATTAAACTGAATACTCGTGTCACTTTAATTCACCAAG  
 ATATTCTACAGTTTCAATCCCTAACAAACAGAGGTATAAAATTTGTTGGG  
 AATATTCCTTACAATTTAAGCACACAAATTATTAAGAAAGTGGTTTTGA  
 AAGCCGTGCGTCTGACATCTATCTGACTGTTGAAGAAGGATTCTACAAGC  
 25 GTACCTTGATATTACCGAACACTAGGGTTGCTCTTGCACTCAAGTC  
 TCGATTACGCAATTGCTTAAGCTGCCAGCGGAATGCTTTCATCCTAAACC  
 AAAAGTAAACAGTGTCTTAATAAACTTACCCGCCATACCACAGATGTTT  
 CAGATAAAATTTGGAAGCTATATAAGTACTTTGTTTCAAATGGGTCAAT  
 CGAGAAATATCGTCAACTGTTTACTAAAAATCAGTTTCGTCAAGCAATGAA  
 ACACGCCAAAGTAAACAATTTAAGTACCATTACTTATGAGCAAGTATTGT  
 CTATTTTTAATAGTTATCTATTATTTAACGGGAGGAAAATAATTCTATGAG  
 TCGCTTTTTTAAATTTGGAAGTTACACGTTACTAAAGGAATGGAGACC  
 GGGGTCGACCCTTCAATAGAGTTCTTAACGTTAATCCGAAAAAACTAAC  
 GTTAATATTAATAAATAAGATCCGCTTGTGAATTATGTATAATTTGATTA  
 GACTAAAGAATAGGAGAAAGTATGATGATATTTAAAAAATTTCTCGTTA  
 AGATAGGTTGTTGGTGAGCATGTTATATACGGATGTATCGGTTTCCTTAA  
 TGCAAAATTTTGTGCTATCTTATTAATTTTTCTATTATATAGATATATT  
 CAAAGAAAGATAACATTTAAACGGATCATATTAGATATTTTAATAGCGAT  
 TATTTTTTCAATATTATATCTGTTTATTTTTCAGATGCGTCATTAATTGTA  
 TGGTATTAATGCGATTAGGGTGGCATTTCATCAACAAAAAGAAAATAAG  
 ATAAAAACGACTGATACAGCTAATTTAATTTCTAATTTATCGTGATCCAGTT  
 ATTGTTAGTTGCGGTTGGGACTATTATTAGTCAGTTTACCATATCGATTA  
 TCAAAAGTGATTTTCAGCCAAAATATATTGAACAATAGTGCAACAGATATA  
 ACTTTATTAGGTATTTCTTTGCTGTTTTATTGACGGCTTGTCTTTTAT  
 ATTATTGAAGAATAAGCGGACTGAATTACAACATTTAAATCAAGAAATCA  
 TTGAATTTTCGTTAGAAAAACAATTTTTATATTTATATTTATTTTATTT  
 ATAGTAATAGAAATATTTTAGCAGTTGGAATCTTCAAGGAGTAACAGC  
 CACGATATTATTAACCATTATCATTATTTTTTGTGTCCTTATCGGGATGA  
 CTTTTTGCAAGTGATGCTTTTTTTGAAGGCTTATTCGATTCGCCAAGAA  
 GCCAATGACCAATTGGTCCGGAATCAACAACCTCAAGATTATCTAGTCAA

14

-continued

TATCGAACAGCAGTACACCGAATTACGGCGATTTAAGCATGATTATCAAAA  
 ACATCTTATTATCGTTGGAGAGTTTTGCGAAAAGGGCGATCAGCAACAG  
 5 TTTAAGGCGTATTACCAAGAATTATTAGCACAACGGCCAATTCAAAGTGA  
 AATCCAAGGGGCGAGTCATTGCACAACCTCGACTACTTGAAAAATGATCCTA  
 TTCGAGGATTAGTCATTCAAAGTTTTTGGCAGCCAAACAGGCTGGTGT  
 10 ACTTTAAAATTCGAAATGACCGAACCAATCGAATTAGCAACCGCTAATCT  
 ATTAACGGTTATTTCGGATTATCGGTATTTTATTAGACAATGCGATTGAAC  
 AAGCCGTTCAAGAAAACCGATCAATTGGTGAGTTGTGCTTTCTTACAATCT  
 15 GATGGTTTAAATCGAAATTACGATTGAAAATACGGCCAGTCAAGTTAAGAA  
 TCTCCAAGCATTTTCAGAGTTAGGCTATTCACGAAAGGCGCTGGTCGGG  
 GGACTGGTTTAGCTAATGTGCAGGATTTGATTGCCAAACAAACCAATTTA  
 20 TTCTTAGAAACACAGATTGAAAATAGAAAGTTACGACAGACATTGATGAT  
 TACGGAGGAACTTAATTTGTATCCCGTTTATTTATTAGAGGATGATTTA  
 CAGCAACAAGCGATTATCAGCAAATATTCGCGAATACGATTATGATTAA  
 25 CGAATTTGCAATGACTTTAACATGCGCTGCCAGTGATACGAGACATGTT  
 TGGCGGCAATTAAGGATCAGCAACGAGGTTTATTCTTTTTGGATATGGAA  
 ATTGAGGATAACCGCAAGCCGGTTTAGAAGTGGCAACTAAGATTCGGCA  
 30 GATGATGCCGTTTTCGCAAAATGTCTTCATTACAACCCACGAGGAAGTGA  
 CATTATTAACGTTAGAACGAAAAATAGCGCCTTTAGATTACATTTCTCAAG  
 GACCAACAATGGCTGAAATCAAAGCAATTGATTGATGATCTATTGTT  
 35 AGCTGAGAAGCAAAACGAGGCGGCAGCGTATCACCGAGAAAATTTATTTA  
 GTTATAAAATAGGTCCTCGCTTTTCTCATTACCATTAAAGGAAGTTGTT  
 TATTTATATACTGAAAAAGAAAATCCGGGTCATATTAATTTGTAGCCGT  
 TACCAGAAAGGTTACTTTTTCCAGGAAATTTAAATGCGCTGGAAGCCCAAT  
 40 ATCCAATGCTCTTTCGGTGTGATAAAAGTTACTTAGTTAACCTATCTAAT  
 ATTGCCAATTATGACAGTAAAACACGGAGTTTAAAATTTGTAGATGGCAG  
 TGAGGCAAAAGTCTCGTTCCGGAATCACGGGAACTAGTGGCCAAATTA  
 45 AACAAATGATGTAGCGCCTGCAGGCACGCCAAATGATCCCAGTAAAAAGC  
 CACCCGATGGCGGGTGGCTTTTTATTAGCCCTAGAAGGGCTTCCACAC  
 GCATTTTCAGCGCCTTAGTGCTTAGTTTGTGAATCATAGGTGGTATAGTC  
 50 CCGAAATACCCGTTAAGGAATTGTCAGATAGGCCTAATGACTGGCTTTT  
 ATAATATGAGATAATGCCGACTGTACTTTTTTACAGTCGGTTTTCTAATGT  
 CACTAACCTGCCCCGTTAGTTGAAGAAGTTTTTATATTACAGCTCCAGA  
 55 TCTACCGGTTTAAATTTGAAAATGATATTAGCGTTTAAACAGTTAAATTA  
 TACGTTAATAATTTTTTGTCTTTAAATAGGGATTTGAAGCATAATGGTG  
 TTATAGCGTACTTAGCTGGCCAGCATATATGTATTTCTATAAAATACTATT  
 60 ACTACCAAGAATAACTTTTCATCGTAAAAGGCAAGTAATTGAGGAACTTG  
AAGTTTTTCTCTATTACTTGCCTTCTTTATTTTATTAAGCTAAATATGTT  
TTAAATAATTAATAACGACCTGCTTGGCGGAACTAAACAGTAAGA  
 65 ACTTTAAATTATAAAAATCTGCAACCGTTTTCTAAAATTTTGGCGCAAGCG

- continued

GTTGCGCAAAATTTTTAAATTTGATATTATTAATATTGCAATAATTCATG  
AAGCGCTTACAATAATCACAAAGTGTCTTTTAGAACTATTTTATAAGTTAA  
GGAGTTGTTAGCAATGCAACAATGCACTTCTTACTTGCAATGGCTCCAC  
 CCCCCTATCATCAACAGTATTTTCAGCATTTCAGGAATGGAAGATAAC  
 TGGATAATATGGCTTTTCGTGTGGTAATTATCATTGACATAATAACAGG  
 GACGGCAAGGAGTTTAGTAACGCATCATAACAACATCAACTAAAGGCACAT  
 CAGGCTTAATCAAGCATGGCATCCTATTAATAATAATCCTGACGCTTTAT  
 CCAATGCTTGATATTAATGGTATGAAAAGCGCCGCGGATACCTTTACGAT  
 GTTTTATGTATTATTCTATGCTGTTTCAATAATTGAGAATTGCGGACAAA

In SEQ ID NO:2 shown above, underline indicates an exemplary terminator sequence, italics indicates an exemplary erythromycin resistant marker, bold underline indicates an exemplary maltose inducible promoter coding sequence, and bold indicates an exemplary holin coding sequence. For generating a stable plasmid in an antibiotic-independent manner, the erythromycin resistant marker can be replaced with the thyA gene, as discussed elsewhere herein. For producing biologics other than holin, the holin coding sequence can be replaced with a coding sequence of a different biologic or a gene product responsible for producing a different biologic.

The microorganism can be engineered using any methods known in the art. General methods are provided in Green et al. 2012. Methods for engineering lactic acid bacteria such as *L. lactis* are provided by van Pijkeren and Britton et al. 2012, van Pijkeren and Neoh et al. 2012, Oh et al. 2014, and Barrangou et al. 2016.

In some versions of the invention, one or more of the biologics are produced by the microorganism and secreted from the microorganism in a maltose-dependent manner without the need for lysis. In the case of polypeptide biologics, for example, the microorganism may comprise a recombinant gene configured to express and secrete the polypeptide. Elements for engineering a microorganism to secrete a polypeptide are well known in the art. Typical elements include a signal peptide-encoding sequence placed upstream of—and in-frame with—the coding sequence of the polypeptide to be secreted. The sequences of a large number of signal peptides for bacteria are known in the art. Exemplary signal peptide sequences are available at <http://www.cbs.dtu.dk/services/SignalP/>. The signal peptide may be cleaved from or remain intact on the polypeptide after secretion.

In certain versions of the invention, the microorganism is administered to a subject in a manner that introduces one or more biologics to the gastrointestinal tract. This can be accomplished at least in part due to the maltose-inducible promoter. Portions of the gastrointestinal tract, such as the small intestine, have relatively high levels of maltose, particularly after the consumption of starch. A microorganism of the invention configured to release a biologic in a maltose-dependent manner can be administered to the gastrointestinal tract, wherein the microorganism will release the biologic in the gastrointestinal tract after exposure to the maltose. If the microorganism is configured to express and directly secrete the biologic in a maltose-dependent manner, the microorganism will secrete the biologic after exposure to the maltose. If the microorganism is configured to express a lytic protein and release a non-secreted biologic, the micro-

organism will lyse and release the non-secreted biologic after exposure to the maltose.

The microorganism can be administered to the gastrointestinal tract by any method known in the art. The microorganism may be administered orally, rectally, or directly into the gastrointestinal tract via a stoma. The microorganism is preferably administered directly into or upstream of the small intestines, so that the microorganism ultimately passes through or into the small intestines. The bacterium may be swallowed or introduced via a tube.

The bacterium may be combined in a composition with a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other material well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the bacterium. The precise nature of the carrier or other material may depend on the route of administration. The composition may be liquid, solid, or semi-solid. The composition may comprise a foodstuff or may take the form of a pharmaceutical composition. Those of relevant skill in the art are well able to prepare suitable compositions.

The subject to which the bacterium is administered may be an animal, such as a mammal or, more specifically, a human.

To ensure there is a sufficient amount of maltose in the gastrointestinal tract to induce release of the biologic therein, maltose or a maltose precursor can be administered to the gastrointestinal tract of the subject before, during, or after administering the microorganism. Any carbohydrate that can be degraded to maltose can serve as a suitable maltose precursor. In some cases, the carbohydrate is degraded to maltose by natural enzymes produced by the subject. In some cases, the carbohydrate is degraded to maltose by enzymes co-administered to the subject along with the maltose precursor. An exemplary maltose precursor is starch. An exemplary enzyme that degrades starch to maltose is amylase (salivary and pancreatic forms). The maltose or maltose precursor (and, optionally, any enzyme responsible for degrading the maltose precursor to maltose) can be administered within (before or after) 5 hours, 4 hours, 3 hours, 2 hours, 1 hour or less of administering the microorganism. The maltose or maltose precursor (and, optionally, any enzyme responsible for degrading the maltose precursor to maltose) is preferably administered in an amount sufficient to stimulate or increase release of the biologic in the subject. The maltose or maltose precursor (and, optionally, any enzyme responsible for degrading the maltose precursor to maltose) may all be administered in the same composition or may be administered in separate compositions.

The administered starch may be substantially purified starch. “Substantially purified starch” refers to processed compositions that contain starch in an amount of at least about 50% w/w, at least about 55% w/w, at least about 60% w/w, at least about 65% w/w, at least about 70% w/w, at least about 75% w/w, at least about 80% w/w, at least about 85% w/w, at least about 90% w/w, or at least about 95% w/w.

In certain versions of the invention, the microorganism is used to produce a biologic in vitro. The microorganism may be cultured in the presence of a sufficient amount of maltose to induce production and/or release of the biologic from the microorganism. The maltose may be provided in the form of maltose or a maltose precursor, either with or without carbohydrate-degrading enzymes. Alternatively or additionally, the microorganism may be primed in a maltose-containing medium and then subsequently cultured in a low-

maltose or no-maltose medium. The microorganism may be cultured in a reactor or other suitable site for producing the biologic.

Due to the lag period associated with gene transcription, the microorganism can be “primed” with maltose at a first time period such that the microorganism releases the biologic at a second time period. This method can be used, for example, for releasing the biologic at sites in the body that do not contain maltose or contain maltose only in low concentrations. This method can alternatively be used for releasing the biologic at in vitro sites that do not contain maltose or contain maltose only in low concentrations. The priming can be performed by contacting the microorganism with a maltose-containing medium prior to administering the microorganism to the subject. The maltose-containing medium preferably comprises an amount of maltose sufficient to induce expression of the gene product, and the contacting is preferably conducted for a time sufficient to induce expression of the gene product. The amount of maltose sufficient to induce expression of the gene product in some cases is a relative amount of maltose with respect to sugars or other factors that may repress expression of the gene product. The contacting is preferably conducted in vitro. The contacting is preferably performed for a time period of from about 10 minutes to about 80 minutes, such as about 20 minutes to about 70 minutes, about 30 minutes to about 60 minutes, about 40 minutes to about 50 minutes, or about 45 minutes. The microorganism is preferably administered to the subject within 60 about minutes, within about 50 minutes, within about 40 minutes, within about 30 minutes, within about 20 minutes, within about 10 minutes, within about 10 minutes, within about 5 minutes, or within about 3 minutes of completing the priming. The microorganism can be administered to the gastrointestinal tract of the subject for release of the biologic therein or to other sites of the subject’s body for release of the biologic therein.

In some versions of the invention, the microorganisms can be configured to enter cells of the subject and release the biologic within the cells of the subject. This can be accomplished by engineering the microorganism to express internalin A (InlA).

The maltose-inducible promoter described herein can also be used for genetic engineering purposes. Efficient genome engineering is key to further improve industrial strains, to engineer probiotics as delivery vehicles, and to understand biological (probiotic) function. The approach of Campbell-like homologous recombination is widely used for genetic engineering purposes, especially for gene insertions and deletions. A commonly used application to modify genomes of lactic acid bacteria is by the application of a temperature-sensitive helper plasmid (that provides RepA in trans) combined with a repA- vector that contains DNA sequences homologous to target locations in the chromosome. Once both vectors are established in the cell, the helper plasmid is cured following growth at increased temperatures, after which the repA- vector is integrated in the chromosome (single-cross over). The latter is typically easily to identify by means of antibiotic selection encoded from the repA-backbone.

There are several shortcomings of the conventional Campbell-like system, however. First, the applicability of high temperatures is unfavorable because it induces increased stress. This increased stress may yield an increase in undesired mutations in the genome, especially when taking into consideration that prolonged culturing of the bacteria at high temperatures is required to cure the helper-

plasmid. Second, the process can take up to one week, after which only approximately 50% of the population is cured from the helper plasmid.

The maltose-inducible promoter combined with repA alleviates all of the above concerns, omitting the need to use the temperature sensitive plasmid. On a previously repA-vector, the maltose promoter fused to repA is cloned. Upon transformation of the bacteria in the presence of maltose, RepA is produced which allows temporarily replication. Transformants (>2,000) are routinely observed in the presence of maltose. However, when the cells are plated on glucose the colony numbers dramatically reduce. This approach allows specific selection for replication, which can be expanded to select for single cross-over. The selection can happen overnight. A schema of this process is shown in FIG. 6.

The elements and method steps described herein can be used in any combination whether explicitly described or not.

All combinations of method steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.

As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise.

Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.

All patents, patent publications, and peer-reviewed publications (i.e., “references”) cited herein are expressly incorporated by reference to the same extent as if each individual reference were specifically and individually indicated as being incorporated by reference. In case of conflict between the present disclosure and the incorporated references, the present disclosure controls.

It is understood that the invention is not confined to the particular construction and arrangement of parts herein illustrated and described, but embraces such modified forms thereof as come within the scope of the claims.

## EXAMPLES

### Microorganisms as Biologic Delivery Vehicles

FIG. 1 shows a schema for an exemplary microorganism of the invention modified for use as a biologic delivery vehicle. The biologic shown in FIG. 1 is a bacteriophage produced by a modified *L. reuteri* microorganism. DNA of a pathogen-derived bacteriophage is fused with a plasmid origin of replication (ORI), a *L. reuteri* auxotrophic marker (thyA), and a CRISPR (Clustered, Regularly Interspaced Short Palindromic Repeats)-cassette to generate a phasmid. The phasmid-encoded auxotrophic marker, when deleted on the *L. reuteri* chromosome, yields stable phasmid replication in *L. reuteri*. The phasmid will produce in *L. reuteri* virions that encode engineered CRISPR arrays. The CRISPR arrays can be designed to target pathogens in a strain-specific manner. Expression of internalin A (InlA) can localize *L. reuteri* intracellularly for subsequent virion release. For extracellular delivery (i.e., in the lumen of the gastrointestinal tract, etc.), InlA is not required. The microorganism can be engineered to lyse and deliver the biologic after ingestion

by harboring a lytic protein gene (holin and/or lysin) operably connected to a promoter that is specifically activated in the presence of maltose, a disaccharide sugar that is abundant in the small intestine of mammals. This leads to expression of the lytic protein (holin and/or lysin), lysis of the microorganism, and delivery of the biologic to its intended destination. In addition to virion delivery, complete lysis is also a robust approach to achieve biological containment.

The schema outlined in FIG. 1 can be used for microorganisms other than *L. reuteri* and biologics other than bacteriophages. For example, a microorganism can stably harbor a maltose-inducible gene encoding a protein biologic (e.g., an antibody, antibiotic, enzyme, etc.) or a protein responsible for making a biologic. Maltose-induced lysis of the microorganism will then release the protein biologic from the microorganism.

#### *Lactobacillus reuteri* as an Exemplary Biologic Delivery Platform

*L. reuteri* is a microorganism amenable to genetic manipulation (van Pijkeren et al. 2009, Oh et al. 2014, van Pijkeren and Britton et al. 2012, van Pijkeren and Neoh et al. 2012, van Pijkeren et al, 2014), is capable of surviving passage through human and murine gastrointestinal tracts (Frese et al. 2010, Oh et al. 2010), and exhibits probiotic features, such as anti-inflammatory properties (Thomas et al. 2012, Liu et al. 2010), prevention of bone loss (Britton et al 2014.), and amelioration of infection by pathogenic *E. coli* (Eaton et al. 2011). These characteristics make *L. reuteri* a suitable exemplary microorganism for use as a platform for delivering biologics to the gastrointestinal tract. The particular *L. reuteri* strain used in the present examples (VPL1014) is an undomesticated strain directly derived from *L. reuteri* ATCC PTA 6475.

#### Antibiotic-Independent Plasmid Stability

In-trans expression of *thyA* in *L. reuteri*  $\Delta$ *thyA* stably maintains extra-chromosomal DNA in the cell. Native *thyA* was inactivated by single-stranded DNA recombineering (van Pijkeren and Britton et al. 2012, van Pijkeren and Neoh et al. 2012) to yield *L. reuteri*  $\Delta$ *thyA*, which makes the cells dependent on exogenously added thymidine in minimal medium. To demonstrate that *L. reuteri*  $\Delta$ *thyA* can be used as a host to stably maintain extra-chromosomal elements that encode *ThyA*, we cloned *thyA* with its native promoter in the backbone of pSIP411 (*Em*<sup>R</sup>), yielding pSIP-*thyA*. *L. reuteri*  $\Delta$ *thyA* harboring pSIP-*thyA* and *L. reuteri* wild-type harboring pSIP411 were cultured in minimal medium lacking thymidine in the absence of antibiotic. Stability of pSIP411 and pSIP-*thyA* was determined by the ratio of total number of cells and *Em*<sup>R</sup> cells. After 50 generations only 20±0.9% of *L. reuteri* wild-type retained pSIP411, while 96±5% of *L. reuteri*  $\Delta$ *thyA* retained pSIP-*thyA*. These data show an approach to maintain unstable plasmids in *L. reuteri*.

#### Induced Lysis for Biologic Delivery and Biological Containment

Lysis is an efficient way to release biologics in situ, and complete lysis achieves biological containment. Native lysin expression can result in lysis of the expression host, as previously demonstrated in *L. lactis* (de Ruyter et al. 1997). The phage search tool (PHAST) (Zhou et al. 2011) revealed the presence of 4 prophages in *L. reuteri* of which 2 are predicted to be intact, all encoding holin-lysin gene clusters. Induced expression of holins alone do induce lysis (de Ruyter et al. 1997, Shi et al. 2012) as a consequence of increased membrane permeability, possibly combined with the presence of native endonucleases.

We cloned a bacteriophage-derived holin gene in the inducible expression vector pSIP57, and confirmed induced lysis in *L. reuteri* (FIG. 2). *L. reuteri* cells harboring pSIP-holin were cultured overnight and diluted to OD600=0.1. At OD600=1 the culture was split, and one culture was induced for holin expression. Expression of the holin lysed *L. reuteri* killing 95% of the population.

These data confirm that we can induce lysis in *L. reuteri*, which we can further optimize and exploit for efficient local biologic release.

#### Maltose-Dependent Lysis

Controlling microorganism lysis can aid with delivery of biologics to various regions in the body, such as the gastrointestinal tract. We identified a promoter in *L. reuteri* that is activated upon sensing maltose, a disaccharide present in the small intestine of mice and humans (Tannock et al. 2011, Fogel et al. 1973). We fused the maltose-inducible promoter to the *L. reuteri* holin gene, and we confirmed lysis of cells when grown in the presence of maltose alone or in a mixture of different ratios of maltose and glucose (FIG. 4).

*L. reuteri* harboring pSIP411 (control) or a pSIP411-derived plasmid containing the holin gene under the control of a maltose-inducible promoter (pVPL3628; FIG. 3; SEQ ID NO:2), was cultured in modified MRS (mMRS) with glucose as a sole carbon source to OD600=0.4. Cells were washed twice in PBS, and resuspended in mMRS containing 100 mM sugar, which was either glucose only (bar#1), maltose only (bar #10) or different ratios of glucose-to-maltose (bars #2-9), i.e. 50-50, 25-75, 12.5-87.5, etc, as indicated in the bottom panel of FIG. 4. After two hours growth, the reduction in OD600 of *L. reuteri* expressing the holin was expressed relative to that of the control as % lysis (primary axis). In analogy, on the secondary axis is the reduction in viability plotted. With a 50-50 mix of glucose and maltose, a 50% reduction of viability was observed for *L. reuteri* expressing the holin.

When *L. reuteri* was cultured in medium containing maltose and equimolar levels of lactose, or fructose, or galactose, or an equimolar mix of these three sugars, the activity of the maltose-inducible promoter was similar to cells cultured in medium containing maltose only (data not shown).

These data demonstrate robust maltose-dependent transcriptional activation. Since *L. reuteri* utilizes mainly non-complex sugars for growth, the present system allows for induced lysis of *L. reuteri* once it reaches the small intestine, which is expected to yield in-situ biologic delivery.

#### Maltose Priming of *L. reuteri*

*L. reuteri* harboring the maltose-inducible holin gene can be primed with maltose to control the timing of lysis after administration. *L. reuteri* harboring pSIP411 (control) or a pSIP411-derived plasmid containing the holin gene under the control of a maltose-inducible promoter (pVPL3628; FIG. 3; SEQ ID NO:2) was cultured in modified MRS (mMRS) with glucose as a sole carbon source to OD600=0.4. Cells were washed twice in PBS, resuspended in mMRS containing 100 mM maltose, and cultured for 45 minutes. After 45 minutes of growth, the cells were transferred to mMRS containing glucose as the sole carbon source, and the OD600 of *L. reuteri* expressing the holin was determined relative to that of the control. As shown in FIG. 5, prior priming of *L. reuteri* harboring the maltose-inducible holin gene in maltose induced lysis even after transfer to glucose-only medium. These data show that priming *L. reuteri* with maltose can be employed for delivering biologics to areas of the body in a manner independent of the maltose concentration at such areas of the body.

## Intracellular Biologic Delivery

*L. reuteri* can be engineered to deliver biologics intracellularly. This can be accomplished by engineering *L. reuteri* to internalize in cells, preferably prior to lysis. Intracellular trafficking and replication of (facultative) anaerobe bacteria are well-established phenomena (Sznol et al. 2000, Cronin et al. 2012, Pálffy et al. 2006). Intracellular entry of *L. reuteri* can be achieved by expression of the *L. monocytogenes* internalin A (InlA) protein, as previously has been shown in *L. lactis* (Guimarães et al. 2005). InlA complexes with E-cadherin and mediates the invasion of LMO in mammalian cells (Lecuit et al. 1997), including in solid breast tumor cells (van Pijkeren et al. 2010). Colorectal cancer (CRC) cells are also of epithelial origin and express E-cadherin (Elzagheid et al. 2006), which allows InlA-mediated invasion. To engineer *L. reuteri* to enter cells, inlA can be codon-optimized for expression in *L. reuteri* and placed under the control of a constitutive promoter, such as P<sub>HELP</sub> (Riedel et al. 2007).

## EXEMPLARY VERSIONS OF THE INVENTION

Exemplary versions of the invention are as follows:

Version 1a. A microorganism harboring a recombinant gene, wherein the recombinant gene comprises a maltose-inducible promoter operably connected to a coding sequence of a first biologic.

Version 2a. The microorganism of version 1a, wherein the maltose-inducible promoter comprises a sequence at least about 80% identical to SEQ ID NO:1.

Version 3a. The microorganism of any one of versions 1a-2a, wherein expression of the first biologic from the coding sequence effects release of the first biologic from the microorganism.

Version 4a. The microorganism of any one of versions 1a-3a, wherein the first biologic comprises a lytic protein.

Version 5a. The microorganism of any one of versions 1a-4a, wherein the first biologic comprises a lytic protein selected from the group consisting of a holin and a lysin.

Version 6a. The microorganism of any one of versions 1a-5a, wherein the first biologic effects lysis of the microorganism.

Version 7a. The microorganism of any one of versions 1a-6a, wherein the first biologic effects release of a second biologic made by the microorganism.

Version 8a. The microorganism of version 7a, wherein the second biologic is selected from the group consisting of a carbohydrate, a polypeptide, a nucleic acid, a metabolite, a virus and a combination thereof.

Version 9a. The microorganism of any one of versions 7a-8a, wherein the microorganism is genetically modified to enhance production of the second biologic.

Version 10a. The microorganism of any one of versions 7a-9a, wherein the second biologic is a polypeptide produced from a recombinant gene.

Version 11a. The microorganism of any one of versions 1a-3a, wherein the first biologic comprises a biologic that is secreted from the microorganism without lysis of the microorganism.

Version 12a. The microorganism of version 11a, wherein the first biologic comprises a polypeptide comprising a signal sequence.

Version 13a. The microorganism of version 1a, wherein the first biologic comprises an RNA.

Version 14a. The microorganism of version 13a, wherein the RNA is an antisense RNA.

Version 15a. The microorganism of any one of versions 1a-14a, wherein the microorganism comprises a bacterium.

Version 16a. The microorganism of any one of versions 1a-15a, wherein the microorganism comprises a member of lactic acid bacteria.

Version 17a. The microorganism of any one of versions 1a-16a, wherein the microorganism comprises a member of *Lactobacillus*.

Version 18a. The microorganism of any one of versions 1a-17a, wherein the microorganism comprises *Lactobacillus reuteri*.

Version 19a. The microorganism of any one of versions 1a-18a, wherein the microorganism comprises a bacterium other than *Lactobacillus reuteri* 100-23.

Version 1b. A method of producing a biologic, the method comprising exposing a microorganism as recited in any one of versions 1a-19a to an amount of maltose sufficient to stimulate production of the first biologic from the coding sequence.

Version 2b. The method of version 1b, wherein the biologic is an RNA.

Version 3c. The method of version 2b, wherein the RNA is an antisense RNA and production of the antisense RNA reduces expression of a gene comprising a sequence complementary to a sequence of the antisense RNA.

Version 1c. A method of introducing a biologic to a site, the method comprising introducing a microorganism harboring a recombinant gene to the site, wherein the recombinant gene comprises a maltose-inducible promoter operably connected to a coding sequence of a first biologic, wherein expression of the first biologic from the coding sequence effects release of the first biologic from the microorganism at the site.

Version 2c. The method of version 1c, wherein the maltose-inducible promoter comprises a sequence at least about 80% identical to SEQ ID NO:1.

Version 3c. The method of any one of versions 1c-2c, wherein the first biologic comprises a lytic protein.

Version 4c. The method of any one of versions 1c-3c, wherein the first biologic comprises a lytic protein selected from the group consisting of a holin and a lysin.

Version 5c. The method of any one of versions 1c-4c, wherein the first biologic effects lysis of the microorganism at the site.

Version 6c. The method of any one of versions 1c-5c, wherein the first biologic effects release of a second biologic made by the microorganism at the site.

Version 7c. The method of version 6c, wherein the second biologic is selected from the group consisting of a carbohydrate, a polypeptide, a nucleic acid, a metabolite, and a combination thereof.

Version 8c. The method of any one of versions 6c-7c, wherein the microorganism is genetically modified to enhance production of the second biologic.

Version 9c. The method of any one of versions 6c-8c, wherein the second biologic is a polypeptide produced from a recombinant gene.

Version 10c. The method of any one of versions 1c-2c, wherein the first biologic comprises a biologic that is secreted from the microorganism without lysis of the microorganism.

Version 11c. The method of version 10c, wherein the first biologic comprises a polypeptide comprising a signal sequence.

Version 12c. The method of any one of versions 1c-11c, wherein the microorganism comprises a bacterium.

Version 13c. The method of any one of versions 1c-12c, wherein the microorganism comprises a member of lactic acid bacteria.

Version 14c. The method of any one of versions 1c-13c, wherein the microorganism comprises a member of *Lactobacillus*.

Version 15c. The method of any one of versions 1c-14c, wherein the microorganism comprises *Lactobacillus reuteri*.

Version 16c. The method of any one of versions 1c-15c, wherein the microorganism comprises a bacterium other than *Lactobacillus reuteri* 100-23.

Version 17c. The method of any one of versions 1c-16c, wherein the introducing the microorganism comprises introducing the microorganism to an in vitro site.

Version 18c. The method of version 17c, wherein the in vitro site comprises an amount of maltose sufficient to induce expression of the gene product.

Version 19c. The method of any one of versions 1c-16c, wherein the introducing the microorganism comprises introducing the microorganism to an in vivo site in a subject.

Version 20c. The method of any one of versions 1c-16c and 19c, wherein the site is a gastrointestinal tract of a subject.

Version 21c. The method of any one of versions 19c-20c, wherein the introducing the microorganism comprises orally administering the microorganism to a subject.

Version 22c. The method of any one of versions 19c-21c, wherein the subject is a mammal.

Version 23c. The method of any one of versions 19c-22c, wherein the subject is a human.

Version 24c. The method of any one of versions 1c-23c, further comprising introducing maltose or a maltose precursor to the site before, during, or after the introducing the microorganism to the site.

Version 25c. The method of version 24c wherein the maltose precursor comprises starch.

Version 26c. The method of any one of versions 1c-25c, further comprising, prior to the introducing the microorganism to the site, contacting the microorganism with a maltose-containing medium.

Version 27c. The method of version 26c, wherein the maltose-containing medium comprises an amount of maltose sufficient to induce expression of the gene product and wherein the contacting is conducted for a time sufficient to induce expression of the gene product.

Version 28c. The method of any one of versions 26c-27c, wherein the contacting is conducted in vitro.

The invention encompasses any combination of the above versions, whether explicitly stated or not.

## CITED REFERENCES

Alvarez-Sieiro P, Montalbán-López M, Mu D, Kuipers O P. Bacteriocins of lactic acid bacteria: extending the family. *Appl Microbiol Biotechnol*. 2016. 100(7):2939-51.

Bahey-El-Din M, Gahan C G M, Griffin B T. 2010. *Lactococcus lactis* as a cell factory for delivery of therapeutic proteins. *Curr Gene Ther* 10:34-45.

Barrangou R, van Pijkeren J P. Exploiting CRISPR-Cas immune systems for genome editing in bacteria. *Curr Opin Biotechnol*. 2016 February; 37:61-8.

Becker S C, Dong S, Baker J R, Foster-Frey J, Pritchard D G, Donovan D M. 2009. LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. *FEMS Microbiol Lett* 294:52-60.

Beisel C L, Goma A A, Barrangou R. 2014. A CRISPR design for next-generation antimicrobials. *Genome Biol* 15:516.

Bikard D, Euler C W, Jiang W, Nussenzweig P M, Goldberg G W, Duportet X, Fischetti V A, Marraffini L A. 2014. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. *Nat Biotech* 32:1146-1150.

Borysowski J, Weber-Dabrowska B, Górski A. Bacteriophage endolysins as a novel class of antibacterial agents. *Exp Biol Med* (Maywood). 2006 April; 231(4):366-77.

Britton, R. A.; Irwin, R.; Quach, D.; Schaefer, L.; Zhang, J.; Lee, T.; Parameswaran, N.; McCabe, L. R. Probiotic *L. reuteri* Treatment Prevents Bone Loss in a Menopausal Ovariectomized Mouse Model. *J Cell Physiol* 2014, 229 (11), n/a-n/a DOI: 10.1002/jcp.24636.

Chatel J-M, Pothelune L, Ah-Leung S, Corthier G, Wal J-M, Langella P. 2008. In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. *Gene Ther* 15:1184-1190.

Cheng X, Zhang X, Pflugrath J W, Studier F W. 1994. The structure of bacteriophage T7 lysozyme, a zinc amidase and an inhibitor of T7 RNA polymerase. *Proc Natl Acad Sci USA* 91:4034-4038.

Citorik R J, Mimee M, Lu T K. 2014. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. *Nat Biotech* 32:1141-1145.

Cotter P D, Ross R P, Hill C. 2013. Bacteriocins [mdash] a viable alternative to antibiotics? *Nat Rev Microbiol* 11:95-105.

Cronin, M.; Akin, A. R.; Collins, S. A.; Meganck, J.; Kim, J.-B.; Baban, C. K.; Joyce, S. A.; van Dam, G. M.; Zhang, N.; van Sinderen, D.; et al. High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. *PLoS ONE* 2012, 7 (1), e30940 DOI:10.1371/journal.pone.0030940.

de Azevedo M, Karczewski J, Lefèvre F, Azevedo V, Miyoshi A, Wells J M, Langella P, Chatel J-M. 2012. In vitro and in vivo characterization of DNA delivery using recombinant *Lactococcus lactis* expressing a mutated form of *L. monocytogenes* Internalin A. *BMC Microbiol* 12:299.

de Ruyter, P. G.; Kuipers, O. P.; Meijer, W. C.; de Vos, W. M. Food-grade controlled lysis of *Lactococcus lactis* for accelerated cheese ripening. *Nat Biotech* 1997, 15 (10), 976-979 DOI:10.1038/nbt1097-976

De Weirdt R, Crabbé A, Roos S, Vollenweider S, Lacroix C, van Pijkeren J-P, Britton R A, Sarker S, Van de Wiele T, Nickerson C A. 2012. Glycerol Supplementation Enhances *L. reuteri*'s Protective Effect against *S. typhimurium* Colonization in a 3-D Model of Colonic Epithelium. *PLoS ONE* 7:e37116.

Dishisha T, Pereyra L P, Pyo S-H, Britton R A, Hatti-Kaul R. 2014. Flux analysis of the *Lactobacillus reuteri* propanediol-utilization pathway for production of 3-hydroxypropionaldehyde, 3-hydroxypropionic acid and 1,3-propanediol from glycerol. *Microb Cell Fact* 13:76.

Doleyres Y, Beck P, Vollenweider S, Lacroix C. 2005. Production of 3-hydroxypropionaldehyde using a two-step process with *Lactobacillus reuteri*. *Appl Microbiol Biotechnol* 68:467-474.

Eaton, K. A.; Honkala, A.; Auchtung, T. A.; Britton, R. A. Probiotic *Lactobacillus reuteri* Ameliorates Disease Due to Enterohemorrhagic *Escherichia coli* in Germfree Mice. *Infect Immun* 2011, 79 (1), 185-191 DOI: 10.1128/IAI.00880-10.

Elzagheid, A.; Algars, A.; Bendardaf, R.; Lamlum, H.; Ristamaki, R.; Collan, Y.; Syrjanen, K.; Pyrhonen, S.

- E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. *World J Gastroenterol* 2006, 12 (27), 4304-4309.
- Feliza A. Bourguet, Brian E. Souza, Angela K. Hinz, Matthew A. Coleman, and Paul J. Jackson. Characterization of a Novel Lytic Protein Encoded by the *Bacillus cereus* E33L Gene ampD as a *Bacillus anthracis* Antimicrobial Protein. *Appl Environ Microbiol.* 2012 April; 78(8): 3025-3027.
- Field D, Connor P M O, Cotter P D, Hill C, Ross R P. 2008. The generation of nisin variants with enhanced activity against specific gram-positive pathogens.—PubMed—NCBI. *Mol Microbiol* 69:218-230.
- Field D, Begley M, O'Connor P M, Daly K M, Hugenholtz F, Cotter P D, Hill C, Ross R P. 2012. Bioengineered Nisin A Derivatives with Enhanced Activity against Both Gram Positive and Gram Negative Pathogens. *PLoS ONE* 7:e46884
- Fischetti V A. 2004. The use of phage lytic enzymes to control bacterial infections, p 321-334 In Kutter E, Sulakvelidze A, editors. (ed), *Bacteriophages: biology and applications*. CRC Press, Boca Raton, Fla.
- Fischetti V A. 2009. *Bacteriophage Lysins: the Ultimate Enzybiotic*. John Wiley & Sons, Inc., Hoboken, N.J., USA
- Fogel, M. R.; Gray, G. M. Starch hydrolysis in man: an intraluminal process not requiring membrane digestion. *J Appl Physiol* 1973, 35 (2), 263-267.
- Frese, S. A.; Hutkins, R. W.; Walter, J. Comparison of the Colonization Ability of Autochthonous and Allochthonous Strains of Lactobacilli in the Human Gastrointestinal Tract. *Advances in Microbiology* 2012, 02 (03), 399-409 DOI: 10.4236/aim.2012.23051.
- Gibson D G, Young L, Chuang R-Y, Venter J C, Hutchison C A, Smith H O. 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat Meth* 6:343-345.
- Good L, Stach J E. Synthetic RNA silencing in bacteria—antimicrobial discovery and resistance breaking. *Front Microbiol.* 2011 Sep. 12; 2:185.
- Gomaa A A, Klumpe H E, Luo M L, Selle K, Barrangou R, Beisel C L. 2014. Programmable Removal of Bacterial Strains by Use of Genome-Targeting CRISPR-Cas Systems. *mBio* 5:e00928-13.
- Green et al., *Molecular Cloning: A Laboratory Manual*, 4th ed., Cold Spring Harbor Laboratory Press, 2012.
- Guimarães, V. D.; Gabriel, J. E.; Lefèvre, F.; Cabanes, D.; Gruss, A.; Cossart, P.; Azevedo, V.; Langella, P. Internalin-expressing *Lactococcus lactis* is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells. *Microbes Infect* 2005, 7 (5-6), 836-844 DOI: 10.1016/j.micinf.2005.02.012.
- Guimarães V, Innocentin S, Chatel J-M, Lefèvre F, Langella P, Azevedo V, 582 Miyoshi A. 2009. A new plasmid vector for DNA delivery using lactococci. *Genet Vaccines Ther* 7:4.
- Jacobs C, Huang L J, Bartowsky E, Normark S, Park J T. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta-lactamase induction. *EMBO J.* 1994 Oct. 3; 13(19):4684-94.
- Jacobs C, Joris B, Jamin M, Klarsov K, Van Beeumen J, Mengin-Lecreulx D, van Heijenoort J, Park J T, Normark S, Frère J M. AmpD, essential for both beta-lactamase regulation and cell wall recycling, is a novel cytosolic N-acetylmuramyl-L-alanine amidase. *Mol Microbiol.* 1995 February; 15(3):553-9.

- Kommineni S, Bretl D J, Lam V, Chakraborty R, Hayward M, Simpson P, Cao Y, Bousounis P, Kristich C J, Salzman N H. 2015. Bacteriocin production augments niche competition by enterococci in the mammalian GI tract. *Nature* 526:719-722.
- Lecuit, M.; Ohayon, H.; Braun, L.; Mengaud, J.; Cossart, P. Internalin of *Listeria monocytogenes* with an intact leucine-rich repeat region is sufficient to promote internalization. *Infect Immun* 1997, 65 (12), 5309-5319.
- Liu, Y.; Fatheree, N. Y.; Mangalat, N.; Rhoads, J. M. Human-derived probiotic *Lactobacillus reuteri* strains differentially reduce intestinal inflammation. *Am J Physiol Gastrointest Liver Physiol* 2010, 299 (5), G1087-G1096 DOI: 10.1152/ajpgi.00124.2010.
- López R, García E, García P, García J L. The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? *Microb Drug Resist.* 1997; 3(2):199-211.
- Loessner M J. Bacteriophage endolysins—current state of research and applications. *Curr Opin Microbiol.* 2005 August; 8(4):480-7.
- Loessner M J, Kramer K, Ebel F, Scherer S. C-terminal domains of *Listeria monocytogenes* bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. *Mol Microbiol.* 2002 April; 44(2):335-49.
- Navarre W W, Ton-That H, Faull K F, Schneewind O. 1999. Multiple Enzymatic Activities of the Murein Hydrolase from Staphylococcal Phage  $\phi$ 11. *Journal of Biological Chemistry* 274:15847-15856.
- Nelson D, Schuch R, Chahales P, Zhu S, Fischetti V A. 2006. PlyC: A multimeric bacteriophage lysin. *Proc Natl Acad Sci USA* 103:10765-10770.
- Nicoletti M, Bertani G. 1983. DNA fusion product of phage P2 with plasmid pBR322: A new phasmid. *Mol Gen Genet* 189:343-347.
- Oh, P. L.; Benson, A. K.; Peterson, D. A.; Patil, P. B.; Moriyama, E. N.; Roos, S.; Walter, J. Diversification of the gut symbiont *Lactobacillus reuteri* as a result of host-driven evolution. *ISME J* 2010, 4 (3), 377-387 DOI: 10.1038/ismej.2009.123.
- Oh J H, van Pijkeren J P. CRISPR-Cas9-assisted recombining in *Lactobacillus reuteri*. *Nucleic Acids Res.* 2014; 42(17):e131.
- Paez-Espino D, Morovic W, Sun C L, Thomas B C, Ueda K-I, Stahl B, Barrangou R, Banfield J F. 2013. Strong bias in the bacterial CRISPR elements that confer immunity to phage. *Nat Comms* 4:1430-1430.
- Pálffy, R.; Gardlík, R.; Hodosy, J.; Behuliak, M.; Resko, P.; Radvánsky, J.; Celec, P. Bacteria in gene therapy: bacteriofection versus alternative gene therapy. *Gene Ther* 2006, 13 (2), 101-105 DOI:10.1038/sj.gt.3302635.
- Riboulet-Bisson E, Sturme M H J, Jeffery I B, O'Donnell M M, Neville B A, Forde B M, Claesson M J, Harris H, Gardiner G E, Casey P G, Lawlor P G, O'Toole P W, Ross R P. 2012. Effect of *Lactobacillus salivarius* Bacteriocin Abp118 on the Mouse and Pig Intestinal Microbiota. *PLoS ONE* 7:e31113.
- Riedel, C. U.; Monk, I. R.; Casey, P. G.; Morrissey, D.; O'Sullivan, G. C.; Tangney, M.; Hill, C.; Gahan, C. G. M. Improved luciferase tagging system for *Listeria monocytogenes* allows real-time monitoring in vivo and in vitro. *Appl Environ Microbiol* 2007, 73 (9), 3091-3094 DOI: 10.1128/AEM.02940-06.
- Robert S, Steidler L. 2014. Recombinant *Lactococcus lactis* can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case. *Microb Cell Fact* 13:S11.

- Schaefer L, Auchtung T A, Hermans K E, Whitehead D, Borhan B, Britton R A. 2010. The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups. *Microbiology* 156:1589-1599.
- Sheehan M M, Stanley E, Fitzgerald G F, van Sinderen D. 1999. Identification and characterization of a lysis module present in a large proportion of bacteriophages infecting *Streptococcus thermophilus*. *Appl Environ Microbiol* 65:569-577.
- Shi, Y.; Yan, Y.; Ji, W.; Bin Du; Meng, X.; Wang, H.; Sun, J. Characterization and determination of holin protein of *Streptococcus suis* bacteriophage SMP in heterologous host. *Virol J* 2012, 9 (1), 70-70 DOI: 10.1186/1743-422X-9-70.
- Steidler L, Hans W, Schotte L, Neiryck S, Obermeier F, Falk W, Fiers W, Remaut E. 2000. Treatment of Murine Colitis by *Lactococcus lactis* Secreting Interleukin-10. *Science* 289:1352-1355.
- Spinler J K, Taweetchotipatr M, Rognerud C L, Ou C N, Tumwasorn S, Versalovic J. 2008. Human-derived probiotic *Lactobacillus reuteri* demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. *Anaerobe* 14:166-171.
- Sulakvelidze, Alexander; Alavidze, Zemphira; and J. Glenn Morris, Jr. Bacteriophage Therapy. *Antimicrob Agents Chemother*. 2001, 45(3): 649-659).
- Summers W C. Bacteriophage therapy. *Annu Rev Microbiol*. 2001; 55:437-51.
- Sznol, M.; Lin, S. L.; Bermudes, D.; Zheng, L.-M.; King, I. Use of preferentially replicating bacteria for the treatment of cancer. *Journal of Clinical Investigation* 2000, 105 (8), 1027-1030 DOI:10.1172/JC19818.
- Talarico T L, Casas I A, Chung T C, Dobrogosz W J. 1988. Production and isolation of reuterin, a growth inhibitor produced by *Lactobacillus reuteri*. *Antimicrob Agents Chemother* 32:1854-1858.
- Tannock, G. W.; Wilson, C. M.; Loach, D.; Cook, G. M.; Eason, J.; O'Toole, P. W.; Holtrop, G.; Lawley, B.

- Resource partitioning in relation to cohabitation of *Lactobacillus* species in the mouse forestomach. *ISME J* 2011, 6 (5), 927-938 DOI: 10.1038/ismej.2011.161.
- Thomas, C. M.; Hong, T.; van Pijkeren, J. P.; Hemarajata, P.; Trinh, D. V.; Hu, W.; Britton, R. A.; Kalkum, M.; Versalovic, J. Histamine Derived from Probiotic *Lactobacillus reuteri* Suppresses TNF via Modulation of PKA and ERK Signaling. *PLoS ONE* 2012, 7 (2), e31951 DOI:10.1371/journal.pone.0037116.g006.
- van Pijkeren, J. P.; Morrissey, D.; Monk, I. R.; Cronin, M.; Rajendran, S.; O'Sullivan, G. C.; Gahan, C. G. M.; Tangney, M. A novel *Listeria monocytogenes*-based DNA delivery system for cancer gene therapy. *Hum. Gene Ther.* 2010, 21 (4), 405-416 DOI: 10.1089/hum.2009.022.
- van Pijkeren J P, Britton R A. High efficiency recombineering in lactic acid bacteria. *Nucleic Acids Res.* 2012 May; 40(10):e76.
- van Pijkeren J-P, Neoh K M, Sirias D, Findley A S, Britton R A. 2012. Exploring optimization parameters to increase ssDNA recombineering in *Lactococcus lactis* and *Lactobacillus reuteri*. *Bioengineered* 3:209-217.
- van Pijkeren, J. P.; Britton, R. A. Precision genome engineering in lactic acid bacteria. *Microb Cell Fact* 2014, 13 Suppl 1, S10-S10 DOI: 10.1186/1475-2859-13-S1-S10
- Wang I N, Smith D L, Young R. 2000. Holins: the protein clocks of bacteriophage infections. *Annual Reviews in Microbiology*
- Wells M. et al. *Lactococcus lactis*: high-level expression of tetanus toxin fragment C and protection against lethal challenge. *Mol. Microbiol.*, 8 (1993), pp. 1155-1162.
- Zhang Y, Eigenbrot C, Zhou L, Shia S, Li W, Quan C, Tom J, Moran P, Di Lello P, Skelton N J, Kong-Beltran M, Peterson A, Kirchhofer D. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. *J Biol Chem.* 2014 Jan. 10; 289(2):942-55.
- Zhou, Y.; Liang, Y.; Lynch, K. H.; Dennis, J. J.; Wishart, D. S. PHAST: A Fast Phage Search Tool. 2011, 39 (suppl), W347-W352 DOI: 10.1093/nar/gkr485.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 2

<210> SEQ ID NO 1

<211> LENGTH: 311

<212> TYPE: DNA

<213> ORGANISM: *Lactobacillus reuteri*

<400> SEQUENCE: 1

```
taccaagaat aactttcatc gtaaaaggca agtaattgag gaaacttgaa gtttttctct      60
attacttgcc ttctttatct tattaagcta aatatgtttt aaataattaa ctataacgga      120
cctgcttggc ggaaactaaa cagtaagaac tttaaattat aaaaatctgc aaccgttttc      180
taaaattttg cgcaagcggg tgcgcaaaat ttttaaattt gatattatta atattgcaat      240
aattcatgaa gcgcttacia taatcacaag tgtcttttag aactatttta taagttaagg      300
agttgtagc a                                                    311
```

<210> SEQ ID NO 2

<211> LENGTH: 6500

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Extrachromosomal plasmid



-continued

&lt;400&gt; SEQUENCE: 2

taatctagac tcgaggaatt cggtagcccg ggttcgaagg cgccaagctt caaattacag	60
cacgtgttgc tttgattgat agccaaaaag cagcagttga taaagcaatt actgatattg	120
ctgaaaaatt gtaatttata aataaaaatc accttttaga ggtgggtttt ttatttataa	180
attattcggt tgatttcgct ttcgatagaa caatcaaagc gagaataagg aagataaatc	240
ccataagggc gggagcagaa tgtccgagac taattcatga gatcgatttt ttattaaaac	300
gtctcaaaat cgtttctgag acgttttagc gtttatttcg tttagttatc ggcataatcg	360
ttaaaacagg cgttatcgta gcgtaaaagc ccttgagcgt agcgtgcttt gcagcgaaga	420
tgttgctctg tagattatga aagccgatga ctgaatgaaa taataagcgc agcgtccttc	480
tatttcgggt ggaggaggct caagggagtt tgagggaatg aaattccctc atggggttga	540
ttttaaaaat tgcttgcaat tttgccgagc ggtagcgtg gaaaaatttt tgaaaaaaat	600
ttggaatttg gaaaaaatg gggggaaagg aagcgaattt tgcttccgta ctacgacccc	660
ccattaagtg ccgagtcca atttttgtgc caaaaacgct ctatcccaac tggctcaagg	720
gtttgagggg tttttcaatc gccaacgaat cgccaacggt ttcgccaacg tttttataa	780
atctatattt aagtagcttt attggtggtt ttatgattac aaagtgatac actaatTTTA	840
taaaattatt tgattggagt tttttaaatg gtgatttcag aatcgaaaaa aagagttatg	900
atctctctga caaaagagca agataaaaaa ttaacagata tggcgaaaca aaaaggTTTT	960
tcaaaatctg cggttgcggc gtttagctata gaagaatag caagaaagga atcagaataa	1020
aaaaaataag cgaaagctcg cgtttttaga aggatacgag ttttcgctac ttgtttttga	1080
taaggtaata tatcatggct attaaatact aaagctagaa attttggatt tttattatat	1140
cctgactcaa ttcctaatga ttggaagaa aaattagaga gtttggcgt atctatggct	1200
gtcagtcctt tacacgatat ggacgaaaaa aaagataaag atacatggaa tagtagtgat	1260
gttatacgaa atggaaagca ctataaaaaa ccacactatc acgttatata tattgcacga	1320
aatcctgtaa caatagaaag cgttaggaac aagattaagc gaaaattggg gaatagttca	1380
gttgctcatg ttgagatact tgattatatc aaaggttcat atgaatattt gactcatgaa	1440
tcaaaggacg ctattgctaa gaataaacat atatacgaca aaaaagatat tttgaacatt	1500
aatgattttg atattgaccg ctatataaca cttgatgaaa gccaaaaaag agaattgaag	1560
aatttacttt tagatatagt ggatgactat aattttggtaa atacaaaaga tttaatggct	1620
tttattcgcc ttaggggagc ggagtttggg attttaataa cgaatgatgt aaaagatatt	1680
gtttcaacaa actctagcgc ctttagatta tggtttgagg gcaattatca gtgtggatat	1740
agagcaagtt atgcaaaggt tcttgatgct gaaacggggg aaataaaatg acaaacaaag	1800
aaaaagagtt atttgctgaa aatgaggaat taaaaaaga aattaaggac ttaaaagagc	1860
gtattgaaag atacagagaa atggaagttg aattaagtac aacaatagat ttattgagag	1920
gagggattat tgaataaata aaagccccc tgacgaaagt cgaagggggc ttttattttg	1980
gtttgatggt gcgattaata gcaatacgat tgcaataaac aaaatgatcc ccttagaagc	2040
aaacttaaga gtgtgttgat agtgcattat cttaaattt tgtataatag gaattgaagt	2100
taaattagat gctaaaaata ggaattgaag ttaaattaga tgctaaaaat ttgtaattaa	2160
gaaggagggg ttcgtcatgt tggattcca aatgcgtaat gtagataaaa catctactgt	2220
tttgaacag actaaaaaca gtgattacgc agataaataa atacgttaga ttaattccta	2280

-continued

---

ccagtgacta	atcttatgac	tttttaaca	gataactaaa	attacaaaca	aatcgtttaa	2340
cttcaggaga	gattacatga	acaaaaatat	aaatatctca	aactttttaa	cgagtgaaaa	2400
agtactcaac	caaataataa	aacaattgaa	tttaaaagaa	accgataccg	tttacgaaat	2460
tggaacaggt	aaagggcatt	taacgacgaa	actggctaaa	ataagtaaac	aggtaacgtc	2520
tattgaatta	gacagtcac	tattcaactt	atcgtcagaa	aaattaaaac	tgaataactcg	2580
tgtcacttta	attcaccaag	atattctaca	gtttcaattc	cctaacaaac	agaggataaa	2640
aattggtggg	aatattcctt	acaatttaag	cacacaaatt	attaaaaaag	tggtttttga	2700
aagcctgctg	tctgacatct	atctgactgt	tgaagaagga	ttctacaagc	gtaccttgga	2760
tattcaccca	acactagggt	tgctcttgca	caactcaagtc	tcgattcagc	aattgcttaa	2820
gctgccagcg	gaatgctttc	atcctaaacc	aaaagtaaac	agtgctctaa	taaaacttac	2880
ccgccatacc	acagatgttc	cagataaata	ttggaagcta	tataagtact	ttgtttcaaa	2940
atgggtcaat	cgagaatata	gtcaactggt	tactaaaaat	cagtttcgtc	aagcaatgaa	3000
acacgcaaaa	gtaaacaatt	taagtacat	tacttatgag	caagtattgt	ctatTTTTAA	3060
tagttatcta	ttatttaacg	ggaggaaata	attctatgag	tcgctttttt	aaatttgga	3120
agttacacgt	tactaaaggg	aatggagacc	ggggtcgacc	cttcaataga	gttcttaacg	3180
ttaatccgaa	aaaaactaac	gttaatatta	aaaaataaga	tccgcttggt	aattatgtat	3240
aatttgatta	gactaaagaa	taggagaaag	tatgatgata	tttaaaaaac	tttctcgta	3300
agatagggtg	ttggtgagca	tgttatatac	ggatgatcgc	gtttccttaa	tgcaaaattt	3360
tgttgctatc	ttattaattt	ttctattata	tagatatatt	caaagaaaga	taacatttaa	3420
acggatcata	ttagatattt	taatagcgat	tattttttca	atattatata	tgtttatttc	3480
agatgcgtca	ttacttgtaa	tggtattaat	gcgattaggg	tggcattttc	atcaacaaaa	3540
agaaaataag	ataaaaacga	ctgatacagc	taatttaatt	ctaattatcg	tgatccagtt	3600
attgtagttt	gcggttgga	ctattattag	tcagtttacc	atatcgatta	tcaaaagtga	3660
tttcagccaa	aatatattga	acaatagtgc	aacagatata	actttattag	gtatTTTctt	3720
tgctgtttta	tttgacggct	tgttctttat	attattgaag	aataagcgga	ctgaattaca	3780
acatttaaat	caagaaatca	ttgaattttc	gttagaaaaa	caatatttta	tatttatatt	3840
tattttattt	atagtaatag	aaattatttt	agcagttggg	aatcttcaag	gagtaacagc	3900
cacgatatta	ttaaccatta	tcattatttt	ttgtgtcctt	atcgggatga	ctttttggca	3960
agtgatgctt	tttttgaagg	cttattcgat	tcgccaagaa	gccaatgacc	aattgggtccg	4020
gaatcaacaa	cttcaagatt	atctagtcaa	tatcgaacag	cagtacaccg	aattacggcg	4080
atttaagcat	gattatcaaa	acatcttatt	atcgttggag	agttttgccg	aaaagggcga	4140
tcagcaacag	tttaaggcgt	attaccaaga	attattagca	caacggccaa	ttcaaagtga	4200
aatccaaggg	gcagtcattg	cacaactcga	ctacttgaaa	aatgatccta	ttcgaggatt	4260
agtcattcaa	aagtttttgg	cagccaaaca	ggctgggtgt	actttaaaat	tcgaaatgac	4320
cgaaccaatc	gaattagcaa	ccgctaattc	attaacgggt	attcggatta	tcggtatttt	4380
atagacaat	gcgattgaac	aagccgttca	agaaaccgat	caattggtga	gttgtgcttt	4440
cttacaatct	gatggtttaa	tcgaaattac	gattgaaaat	acggccagtc	aagttaagaa	4500
tctccaagca	ttttcagagt	taggctattc	aacgaaaggc	gctggtcggg	ggactggttt	4560
agctaattgtg	caggatttga	ttgccaaaca	aaccaattta	ttcttagaaa	cacagattga	4620
aaatagaaag	ttacgacaga	cattgatgat	tacggaggaa	acttaatttg	tatcccgttt	4680

-continued

---

atttattaga	ggatgattta	cagcaacaag	cgatttatca	gcaaattatc	gcgaatacga	4740		
ttatgattaa	cgaatttgca	atgactttaa	catgcgctgc	cagtgatact	gagacattgt	4800		
tggcggcaat	taaggatcag	caacgagggt	tattcttttt	ggatatggaa	attgaggata	4860		
accgccaagc	cggtttagaa	gtggcaacta	agattcggca	gatgatgccg	tttgcgcaaa	4920		
ttgtcttcat	tacaaccac	gaggaactga	cattattaac	gttagaacga	aaaatagcgc	4980		
ctttagatta	cattctcaag	gaccaaacia	tggctgaaat	caaaaggcaa	ttgattgatg	5040		
atctattggt	agctgagaag	caaaacgagg	cggcagcgta	tcaccgagaa	aatttattta	5100		
gttataaaat	aggctctcgc	tttttctcat	taccattaaa	ggaagttggt	tatttatata	5160		
ctgaaaaaga	aatccgggt	catattaatt	tgttagccgt	taccagaaag	gttacttttc	5220		
caggaaattt	aatgcgctg	gaagcccaat	atccaatgct	ctttcggtgt	gataaaagtt	5280		
acttagttaa	cctatcta	attgcccaat	atgacagtaa	aacacggagt	ttaaaatttg	5340		
tagatggcag	tgaggcaaaa	gtctcgttcc	ggaaatcacg	ggaactagt	gccaaattaa	5400		
aacaaatgat	gtagegcctg	caggcacgcc	aatgatccc	agtaaaaagc	caccgcgatg	5460		
gcgggtggct	ttttattagc	cctagaaggg	cttcccacac	gcatttcagc	gccttagtgc	5520		
cttagtttgt	gaatcatagg	tggatatagc	ccgaaatacc	cgtctaagga	attgtcagat	5580		
aggccta	actggctttt	ataatagag	ataatgccga	ctgtactttt	tacagtcggt	5640		
tttcta	actaacctg	ccccgttagt	tgaagaaggt	ttttatatta	cagctccaga	5700		
tctaccggtt	taatttgaaa	attgatatta	gcgtttaaca	gttaaattaa	tacgttaata	5760		
atTTTTT	ctttaa	aggattgaag	cataatggtg	ttatagcgt	cttagctggc	5820		
cagcatatat	gtattctata	aaatactatt	actaccaaga	ataactttca	tcgtaaaagg	5880		
caagtaattg	aggaaactg	aagtttttct	ctattacttg	ccttctttat	tttattaagc	5940		
taaat	atggtt	ttaaataatt	aactataacg	gacctgcttg	gcggaaacta	aacagtaaga	6000	
acttta	aatct	ataaaaatct	gcaaccgttt	tctaaaattt	tgcgcaagcg	gttgcgcaaa	6060	
atTTTT	aat	ttgatattat	taatattgca	ataattcatg	aagcgcttac	aataatcaca	6120	
agtgtctttt	agaactat	ttataag	ttaa	ggagttg	tta	gcaatgcaaa	caatgcactt	6180
cttacttgca	atggctccac	ccccgtatca	tcaacag	tat	ttcagcatt	ttcaaggaat	6240	
ggaagataac	tggataat	at	ggcttttcgt	gtggg	taatt	atcattgaca	taataacagg	6300
gacggcaagg	agtttag	ta	cgcatc	atac	aaaggc	acat	caggctta	6360
caagcatggc	atcctatt	ta	ataatcct	gacgcttt	at	ccaatgcttg	atattaatgg	6420
tatgaaaagc	gccggcgata	cctttac	gat	gtttatg	ta	ttattctatg	ctgtttca	6480
aattgagaat	tgcgga	caaa					6500	

---

What is claimed is:

1. A method of introducing a biologic to a site, the method comprising introducing a microorganism harboring a recombinant gene to the site, wherein the recombinant gene comprises a maltose-inducible promoter operably connected to a coding sequence of a first biologic, wherein the maltose-inducible promoter is at least about 90% identical to the sequence of SEQ ID NO:1, wherein expression of the first biologic from the coding sequence effects release of the first biologic from the microorganism at the site.

2. The method of claim 1, wherein the first biologic comprises a lytic protein that effects lysis of the microorganism at the site.

55 3. The method of claim 2, wherein the microorganism is genetically modified to produce a second biologic, and wherein production of the first biologic effects release of the second biologic at the site.

4. The method of claim 3, wherein the site is an in vitro site comprising an amount of maltose sufficient to induce expression of the first biologic.

5. The method of claim 4, wherein the lytic protein comprises a holin.

6. The method of claim 3, wherein the site is a gastrointestinal tract of a subject.

7. The method of claim 6, further comprising introducing maltose or a maltose precursor to the gastrointestinal tract

35

before, during, or after the introducing the microorganism to the gastrointestinal tract in an amount sufficient to induce expression of the first biologic in the gastrointestinal tract.

8. The method of claim 7, wherein the lytic protein comprises a holin.

9. The method of claim 3, further comprising, prior to the introducing the microorganism to the site, contacting the microorganism with a maltose-containing medium comprising an amount of maltose sufficient to induce expression of the first biologic, wherein the contacting is conducted for a time sufficient to induce expression of the first biologic.

10. The method of claim 9, wherein the site is a gastrointestinal tract of a subject, and wherein the contacting is conducted in vitro.

11. The method of claim 10, wherein the lytic protein comprises a holin.

12. The method of claim 1, wherein the coding sequence of the first biologic encodes a polypeptide comprising a signal sequence.

13. The method of claim 1, wherein the site is an in vitro site comprising an amount of maltose sufficient to induce expression of the first biologic.

14. The method of claim 1, wherein the site is an in vivo site in a subject.

15. The method of claim 1, wherein the site is a gastrointestinal tract of a subject.

36

16. The method of claim 15, further comprising introducing maltose or a maltose precursor to the gastrointestinal tract before, during, or after the introducing the microorganism to the gastrointestinal tract in an amount sufficient to induce expression of the first biologic in the gastrointestinal tract.

17. The method of claim 1, further comprising, prior to the introducing the microorganism to the site, contacting the microorganism with a maltose-containing medium comprising an amount of maltose sufficient to induce expression of the first biologic, wherein the contacting is conducted for a time sufficient to induce expression of the first biologic.

18. The method of claim 17, wherein the site is a gastrointestinal tract of a subject, and wherein the contacting is conducted in vitro.

19. A method of producing a biologic, the method comprising exposing a microorganism to an amount of maltose, wherein the microorganism harbors a recombinant gene, wherein the recombinant gene comprises a maltose-inducible promoter operably connected to a coding sequence of a first biologic, wherein the maltose-inducible promoter is at least about 90% identical to the sequence of SEQ ID NO:1, wherein the amount of maltose is sufficient to stimulate production of the first biologic from the coding sequence.

\* \* \* \* \*